Azaspirane derivatives as stearoyl-coa desaturase 1 inhibitors
By providing azaspirane derivatives as SCD1 inhibitors, the problem of systemic side effects of existing SCD1 inhibitors has been solved, achieving effective treatment and prevention of SCD1-mediated diseases.
Patent Information
- Application Number
- CN202310572826.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-22
- Publication Date
- 2024-11-22
AI Technical Summary
Existing technologies are unable to effectively inhibit stearoyl-CoA desaturase 1 (SCD1), resulting in poor treatment outcomes for related diseases such as lipid disorders, metabolic syndrome, skin diseases, diabetes, and cancer. Furthermore, systemic inhibitors may cause side effects.
A class of azaspirane derivatives is provided as SCD1 inhibitors, which can reduce systemic side effects through local administration and are used to treat and prevent SCD1-mediated diseases and conditions.
This azaspirane compound can effectively inhibit SCD1, reduce the side effects of topical administration, and achieve the treatment and prevention of diseases such as lipid disorders, metabolic syndrome, skin diseases, diabetes and cancer.
Smart Images

Figure CN118993978A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medicinal chemistry, and specifically relates to a class of organic compounds as stearoyl-CoA desaturase 1 inhibitors, which are used to treat and / or prevent related diseases mediated by stearoyl-CoA desaturase 1, including diseases and conditions related to abnormal lipid levels, metabolic syndrome, weight disorders, skin diseases, fatty liver disease, diabetes and cancer, etc. Specifically, the present invention relates to azaspirane derivatives or pharmaceutically acceptable salts thereof, preparation methods, and pharmaceutical compositions and uses containing these compounds. Background Art
[0002] Stearoyl-CoA Desaturase (SCD) is a member of the dehydrogenase family. SCD in mammals is divided into 5 subtypes, of which the mouse SCD gene has 4 subtypes (mSCD1, mSCD2, mSCD3 and mSCD4), the rat SCD gene has 2 subtypes rSCD1 and rSCD2, and the human SCD gene has 2 subtypes, hSCD1 and hSCD5. The homology between the hSCD1 gene and the mSCD1 gene reaches 85%. Different subtypes of human SCD genes are expressed in different tissues. hSCD1 is highly expressed in adipose tissue, liver, lung, brain, heart, breast, skeletal muscle and skin, and hSCD5 is only expressed in the brain and pancreas. The homology between hSCD1 and hSCD5 is about 54%.
[0003] In mammals, SCD1 is an important metabolic enzyme that forms monounsaturated fatty acids during fatty acid synthesis. It is anchored on the endoplasmic reticulum membrane and tightly bound to nicotinyl coenzyme NAD(P), cytochrome b5 reductase and cytochrome b5. It catalyzes the conversion of saturated fatty acids (mainly catalyzing the Δ-9 cis-desaturation of stearoyl-CoA and palmitoyl-CoA) into unsaturated fatty acids (oleoyl-CoA and palmitoleoyl-CoA) in the presence of oxygen and iron ions. Unsaturated fatty acids can be further catalyzed into polyunsaturated fatty acids, thereby participating in the synthesis of various lipids including triglycerides, phospholipids, cholesterol esters, wax esters and alkyl-1,2-diacylglycerols.
[0004] The ratio of stearate to oleate is one of the factors that influence membrane fluidity, and its changes play an important role in obesity, diabetes, vascular and heart diseases, and cancer. Clinically, it has been observed that the SCD1 content is increased in obese and metabolic syndrome subjects. Obese subjects have a higher ratio of unsaturated fatty acids to saturated fatty acids compared to healthy people.
[0005] SCD1 is widely distributed in the human body, involved in many signaling pathways, and has different functions in different tissues. Previous animal experiments have found that systemic inhibition of SCD1 can cause some adverse reactions in the body, such as eyelid closure. In order to avoid the adverse reactions of systemic administration of SCD1 inhibitors, local administration is considered to reduce systemic side effects.
[0006] In the mouse model experiment of specific knockout of SCD1 gene on the skin, it was found that knocking out SCD1 can resist obesity caused by high-fat diet, improve glucose sensitivity, increase resting metabolic rate, increase energy consumption and reduce fat content in tissues such as liver and subcutaneous tissue. Such studies suggest that inhibiting SCD1 on the skin can regulate diseases such as lipid and weight disorders, metabolic syndrome, skin diseases, diabetes and cancer.
[0007] As compounds that inhibit the activity of SCD1 on the skin, compounds described in Patent Documents 1-4 are known. Non-patent literature reports that skin knockout of SCD1 causes physiological changes in mice. The present invention solves this problem by providing a novel azaspiro derivative. The compound is used to treat and / or prevent SCD1-mediated diseases and conditions, such as lipid disorders, weight disorders, metabolic syndrome, skin diseases, diabetes and cancer.
[0008] [Reference list]
[0009] [Patent Document]
[0010] Patent Document 1: WO 2009 / 106991
[0011] Patent Document 2: WO 2009 / 019566
[0012] Patent Document 3: WO 2017 / 214201
[0013] Patent Document 4: WO 2022 / 178261
[0014] [Non-patent literature]
[0015] Non-patent document 1: Xin et al., Bioorg. Med. Chem. Lett. 2008, 18(15):4298-302
[0016] Non-patent document 2: Meingassner et al., J. Invest Dermatol. 2013, 133(8):2091-4
[0017] Non-patent document 3: Khandelwal et al., Lipid Res. 2014, 55(7):1366-74
[0018] Non-patent literature 4: Brigandi et al., Clin Pharmacol Drug Dev. 2019, 8(3):270-280 Summary of the invention
[0019] [Problems to be Solved by the Invention]
[0020] An object of the present invention is to provide an azaspirane derivative. The azaspirane compound has a stearoyl-CoA desaturase 1 inhibitory effect and is expected to be used to prevent and / or treat related diseases mediated by stearoyl-CoA desaturase 1, including diseases and conditions related to abnormal lipid levels, cardiovascular diseases, diabetes, obesity, metabolic syndrome, skin diseases and cancer.
[0021] [Methods of solving the problem]
[0022] In order to try to solve the above problems, the compounds of the present invention and their pharmaceutical compositions can be used as SCD1 inhibitors. In certain embodiments, the present invention provides compounds of formula (I) having SCD1 inhibitory effects, thereby completing the present invention.
[0023] In certain embodiments, the present invention provides compounds of formula (I):
[0024] (I)
[0025] or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer or racemate thereof;
[0026] in,
[0027] m and n are each independently 0 or 1;
[0028] X and Y together form a cyclopropyl, cyclobutyl or cyclopentyl group;
[0029] U and V together form a cyclopropyl, cyclobutyl or cyclopentyl group;
[0030] W is an oxygen atom;
[0031] Q is independently selected from aryl or heteroaryl;
[0032] R1 is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C3-C6 cycloalkyl, halogen, optionally halogenated C1-C6 alkyl, C1-C6 alkoxy, optionally halogenated C1-C6 alkoxy, C3-C6 cycloalkyloxy, optionally halogenated C3-C6 cycloalkyloxy;
[0033] R2 is independently selected from hydrogen, hydroxy, hydroxy-substituted C1-C6 alkyl, C1-C6 alkyl, C3-C6 cycloalkyl, halogen, optionally halogenated C1-C6 alkyl, C1-C6 alkoxy, optionally halogenated C1-C6 alkoxy, C3-C6 cycloalkyloxy, optionally halogenated C3-C6 cycloalkyloxy, alkoxyalkyl, nitro, cyano, aminosulfonyl, amino, C1-C6 alkylamino, -C(O)NH(R3);
[0034] R3 is independently selected from hydrogen or C1-C6 alkyl.
[0035] In certain embodiments, the present invention provides compounds of formula (I) having the following formula (Ia):
[0036] (Ia)
[0037] or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer, or racemate thereof;
[0038] in,
[0039] m is independently 0 or 1;
[0040] U and V together form a cyclopropyl, cyclobutyl or cyclopentyl group;
[0041] W is an oxygen atom;
[0042] Q is independently selected from aryl or heteroaryl;
[0043] R1 is independently selected from hydrogen, halogen, optionally halogenated C1-C6 alkyl;
[0044] R2 is independently selected from hydrogen, hydroxy, hydroxy-substituted C1-C6 alkyl, C1-C6 alkyl, C3-C6 cycloalkyl, halogen, optionally halogenated C1-C6 alkyl, C1-C6 alkoxy, optionally halogenated C1-C6 alkoxy, C3-C6 cycloalkyloxy, optionally halogenated C3-C6 cycloalkyloxy, alkoxyalkyl, nitro, cyano, aminosulfonyl, amino, C1-C6 alkylamino, -C(O)NH(R3);
[0045] R3 is independently selected from hydrogen or C1-C6 alkyl.
[0046] In certain embodiments, the present invention provides compounds of formula (I) having the following formula (Ib):
[0047] (Ib)
[0048] or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer or racemate thereof;
[0049] in,
[0050] U and V together form a cyclopropyl, cyclobutyl or cyclopentyl group;
[0051] Q is independently selected from aryl or heteroaryl;
[0052] R1 is independently selected from hydrogen, halogen, optionally halogenated C1-C6 alkyl;
[0053] R2 is independently selected from hydrogen, hydroxy, hydroxy-substituted C1-C6 alkyl, C1-C6 alkyl, C3-C6 cycloalkyl, halogen, optionally halogenated C1-C6 alkyl, C1-C6 alkoxy, optionally halogenated C1-C6 alkoxy, C3-C6 cycloalkyloxy, optionally halogenated C3-C6 cycloalkyloxy, alkoxyalkyl, nitro, cyano, aminosulfonyl, amino, C1-C6 alkylamino, -C(O)NH(R3);
[0054] R3 is independently selected from hydrogen or C1-C6 alkyl.
[0055] In certain embodiments, the present invention provides a compound of formula (I) having the following formula (Ic):
[0056] (Ic)
[0057] or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer or racemate thereof;
[0058] in,
[0059] Q is independently selected from aryl or heteroaryl;
[0060] R1 is independently selected from trifluoromethyl or halogen;
[0061] R2 is independently selected from hydrogen, hydroxy, hydroxy-substituted C1-C6 alkyl, halogen, -C(O)NH(R3);
[0062] R3 is independently selected from hydrogen or C1-C6 alkyl.
[0063] In certain embodiments, the present invention provides compounds of formula (Ic), wherein R1 is trifluoromethyl and Q is independently selected from
[0064] , ;
[0065] R2 is independently selected from hydroxy-substituted C1-C6 alkyl, halogen, -C(O)NH(R3);
[0066] R3 is independently selected from hydrogen or C1-C6 alkyl.
[0067] In certain embodiments, the present invention provides a compound of formula (I) having the following formula (Id):
[0068] (Id)
[0069] or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer or racemate thereof;
[0070] in,
[0071] R1 is independently selected from trifluoromethyl or halogen;
[0072] R2 is independently selected from C1-C6 alkyl substituted with hydroxy, C1-C6 alkyl.
[0073] In certain embodiments, the present invention provides a compound of formula (I) having the following formula (Ie):
[0074] (Ie)
[0075] or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer or racemate thereof;
[0076] in,
[0077] R1 is independently selected from trifluoromethyl or halogen;
[0078] R2 is independently selected from C1-C6 alkyl substituted with hydroxy.
[0079] In certain embodiments, the present invention provides the following compounds:
[0080] 1) ,
[0081] 2) ,
[0082] 3) ,
[0083] 4) ,
[0084] 5) or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
[0085] In certain embodiments, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a solvate or hydrate of the compound or its salt, and a pharmaceutically acceptable carrier, vehicle, diluent or excipient.
[0086] In certain embodiments, the present invention provides the use of a compound of formula (I) and a pharmaceutical composition thereof in the preparation of a medicament for treating and / or preventing a stearoyl-CoA desaturase 1-mediated related disorder, disease or condition in a patient.
[0087] In certain embodiments, the present invention provides (I) compounds or pharmaceutical compositions thereof for use in treating and / or preventing a stearoyl-CoA desaturase 1-mediated disorder, disease or condition selected from lipid disorders, metabolic syndrome, weight disorders, skin diseases, fatty liver disease, diabetes and cancer in a patient.
[0088] In certain embodiments, the present invention provides a compound of formula (I) or a pharmaceutical composition thereof for use in treating and / or preventing a disease selected from a combination of dyslipidemia, hyperlipidemia, hypertriglyceridemia, atherosclerosis, hypercholesterolemia, low high-density lipoprotein and high low-density lipoprotein, dyslipidemia, diabetes, impaired glucose tolerance, obesity, insulin resistance, hypertension, hypertriglyceridemia, increased abdominal circumference, low high-density lipoprotein, microalbuminemia, hyperuricemia and / or hypercoagulability.
[0089] In certain embodiments, the present invention provides a compound of formula (I) or a pharmaceutical composition thereof for use in treating and / or preventing a disease selected from eczema, acne, rosacea, seborrheic dermatitis, oily skin, rosacea, keloid scarring or preventing or having other skin conditions caused by lipid imbalance.
[0090] In certain embodiments, the present invention provides a compound of formula (I) or a pharmaceutical composition thereof for use in treating and / or preventing a disease selected from non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and liver cirrhosis.
[0091] In certain embodiments, the present invention provides a disease for treatment and / or prevention by administering a compound of formula (I) or a pharmaceutical composition thereof selected from renal cell carcinoma, liver cancer, bladder cancer, breast cancer, lung cancer, prostate cancer, ovarian cancer, colon cancer, melanoma, pancreatic cancer, thyroid cancer.
[0092] In certain embodiments, the present invention provides a compound of formula (I) or a pharmaceutical composition thereof for use in treating and / or preventing a stearoyl-CoA desaturase 1-mediated disorder, disease or condition selected from lipid disorders, metabolic syndrome, weight disorders, skin diseases, fatty liver disease, diabetes and cancer and further comprising administering a second therapeutic agent for treating and / or preventing lipid disorders, metabolic syndrome, weight disorders, skin diseases, fatty liver disease, diabetes and cancer.
[0093] In certain embodiments, the present invention provides methods and intermediates for preparing the compounds of the present invention.
[0094] In certain embodiments, the present invention provides compounds of the present invention for use in therapy.
[0095] [Effects of the Invention]
[0096] According to the present invention, an azaspirane derivative is provided. The azaspirane compound has a stearoyl-CoA desaturase 1 inhibitory effect and is expected to be used to prevent and / or treat diseases mediated by stearoyl-CoA desaturase 1, including diseases and conditions related to abnormal lipid levels, cardiovascular diseases, diabetes, obesity, metabolic syndrome, skin diseases and cancer. DETAILED DESCRIPTION
[0097] the term
[0098] The following are definitions of all terms used in this specification and the appended claims. Unless otherwise indicated, the initial definition provided herein for a group or term applies to that group or term in this specification and claims alone or as part of another group.
[0099] The abbreviations preceding certain chemical groups named herein represent the total number of carbon atoms present in the designated chemical group. For example, C1-C6 alkyl represents an alkyl group as defined below having a total of 1-6 carbon atoms, C1-C6 alkoxy represents an alkoxy group as defined below having a total of 1-6 carbon atoms, C3-C6 cycloalkyl represents a cycloalkyl group as defined below having a total of 3-6 carbon atoms, and C3-C6 cycloalkoxy represents a cycloalkoxy group as defined below having a total of 3-6 carbon atoms. The total number of carbons in the abbreviations does not include carbons that may be present in the substituents of the above groups.
[0100] The compounds of the present invention may have one or more asymmetric centers. Unless otherwise indicated, all chiral (enantiomers and diastereomers), racemic forms and atropisomers of the compounds of the present invention are included in the present invention. These compounds may also have many geometric isomers of olefins, C=N double bonds, etc., and all such stable isomers are included in the present invention. The cis and trans geometric isomers of the compounds of the present invention are described and can be separated into isomeric mixtures or separated isomeric forms. The compounds of the present invention can be separated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, for example, by splitting racemic forms or by synthesizing from optically active starting materials. Unless a specific stereochemistry or isomeric form is clearly indicated, it is intended to include all chiral (enantiomeric and diastereomeric) and racemic forms of a structure and all geometric isomeric forms.
[0101] When a bond to a substituent is shown as passing through a bond connecting two atoms in a ring, then the substituent may be attached to any atom on the ring. When a substituent is listed without indicating the atom via which the substituent is attached to the rest of the compound of a given formula, then the substituent may be attached via any atom in the substituent; combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.
[0102] According to the practice in this field, The bonds used in the formulae herein to describe the points of attachment of the moiety or substituent to the parent core or structure.
[0103] A dash "-" not appearing between two letters or symbols is used to indicate the point of attachment of a substituent; for example, -C(O)NH(R3) is attached through a carbon atom.
[0104] "Optional" or "optionally from" means that the subsequently described event may or may not occur, and the description includes cases where the described event or situation occurs and cases where it does not.
[0105] The term "optionally substituted" (e.g., optionally substituted alkyl) in reference to a particular group of compounds of formula (I) refers to a group having zero, one, two or more substituents. For example, "optionally substituted alkyl" encompasses "alkyl" and "substituted alkyl", as defined below. It will be understood by those skilled in the art that for any group containing one or more substituents, these groups do not introduce any sterically impractical, synthetically unfeasible and / or inherently unstable substitutions or substitution patterns.
[0106] As used herein, the terms "compound of formula (I)", "compound of the present invention" and "compound" are used interchangeably in this application and should all be considered to have the same meaning.
[0107] As used herein, the term "alkyl" refers to a branched and branched saturated aliphatic hydrocarbon group including a specified number of carbon atoms. For example, "C1-C6 alkyl" refers to a C1, C2, C3, C4, C5 and C6 alkyl group. In addition, for example, "C1-C6 alkyl" means an alkyl group having 1 to 6 carbon atoms; the alkyl group may be unsubstituted or substituted so that one or more of its hydrogens are replaced by another chemical group; examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, tert-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), and the like.
[0108] The term "alkoxy" refers to an oxygen atom substituted with an alkyl or substituted alkyl as defined herein. For example, the term "alkoxy" includes the group -OC 1-6Alkyl groups, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentyloxy, 2-pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, 2-hexyloxy, 3-hexyloxy, 3-methylpentyloxy and the like.
[0109] As used herein, the term "substituted" refers to the replacement of any one or more hydrogens on a designated atom or group by the selection of a designated group, provided that the normal valence of the designated atom is not exceeded. When the substituent is an oxo or keto group (i.e., =O), then 2 hydrogens on the atom are replaced. Keto substituents are not present on aromatic moieties. Unless otherwise indicated, the substituents are named into the core structure; for example, it is understood that when (cycloalkyl) alkyl is listed as a possible substituent, the point of attachment of the substituent to the core structure is in the alkyl portion; as used herein, a ring double bond is a double bond formed between two adjacent ring atoms (e.g., C=C, C=N, or N=N).
[0110] Combinations of substituents and / or variables are permissible only if these combinations result in stable compounds or useful synthetic intermediates; "stable compounds" and "stable structures" are meant to be compounds that are sufficiently stable to survive isolation to a useful degree of purity from a reaction mixture and formulation into an efficacious therapeutic agent. The skilled artisan will recognize unstable combinations of substituents.
[0111] The term "cycloalkyl" refers to a cyclized alkyl group, including monocyclic, bicyclic or polycyclic ring systems. C3-C6 cycloalkyl refers to C3, C4, C5 and C6 cycloalkyl groups; examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
[0112] The term "aryl" refers to a monocyclic or bicyclic aromatic hydrocarbon group having 6 to 12 carbon atoms in the ring portion, for example, phenyl and naphthyl, each of which may be substituted.
[0113] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0114] The term "haloalkyl" refers to a substituted alkyl group having one or more halogen substituents, for example, trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, 3-bromo-2-fluoropropyl, 1-bromomethyl-2-bromoethyl, etc. The alkyl portion of the haloalkyl group may be optionally substituted as defined above for an alkyl group.
[0115] The term "haloalkoxy" refers to an alkoxy group having one or more halogen substituents, for example, "haloalkoxy" includes -OCF3. The alkoxy portion of the haloalkoxy group may be optionally substituted as defined above for an alkoxy group.
[0116] The term "aryl" when used alone or as part of a larger moiety such as in "aralkyl", "aralkyloxy" or "aryloxyalkyl" refers to a monocyclic or bicyclic ring system having a total of 5 to 14 ring members, wherein at least one ring in the system is aromatic and wherein each ring of the system contains 3 to 7 ring members. In certain embodiments of the present invention, "aryl" refers to an aromatic ring system, which includes but is not limited to phenyl, biphenyl, naphthyl, anthracenyl, etc., which may carry one or more substituents. As used herein, the term "aryl" also includes within its scope groups in which an aromatic ring is fused to one or more non-aromatic rings, for example, indanyl, phthalimidyl, phthalimidyl, phenanthridinyl or tetrahydronaphthyl, etc.
[0117] The term "heteroaryl" refers to substituted and unsubstituted aromatic five- or six-membered monocyclic radicals, nine- or ten-membered bicyclic radicals, and eleven- to fourteen-membered tricyclic radicals having at least one heteroatom in at least one ring, the heteroatom-containing ring preferably having 1, 2 or 3 heteroatoms selected from oxygen, sulfur and nitrogen; each heteroatom-containing ring of the heteroaryl radical may contain 1 or 2 oxygen or sulfur nuclei and / or 1 to 4 single atoms, provided that the total number of heteroatoms in each ring is 4 or less and each ring has at least one carbon atom; the fused rings completing the bicyclic and tricyclic radicals may contain only carbon atoms and may be saturated, partially saturated or unsaturated; the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atom may optionally be quaternized. Heteroaryl groups that are bicyclic or tricyclic must include at least one fully aromatic heterocyclic ring, but the other fused ring or rings may be aromatic or non-aromatic; the heteroaryl group may be attached at any available nitrogen or carbon atom of any ring; if the other ring is a cycloalkyl or heterocyclic ring, it is further optionally substituted with =0 (oxo) when the compound permits.
[0118] Exemplary monocyclic heteroaryl groups include pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl.
[0119] Exemplary cycloheteroaryl groups include indolyl, benzothiazolyl, benzodioxolyl, benzoxazolyl, benzothiazolyl, quinolyl, tetrahydroisoquinolyl, isoquinolyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridinyl, furopyridinyl, dihydroisoindolyl, tetrahydroquinolyl, and the like.
[0120] Exemplary tricyclic heteroaryl groups include carbazolyl, benzindolyl, phenanthrolinyl, acridinyl, phenanthridinyl, xanthenyl, and the like.
[0121] The term "heteroatom" shall include oxygen, sulfur and nitrogen.
[0122] The term "heterocycle" refers to a stable 5-7-membered monocyclic or 7-10-membered bicyclic saturated or partially saturated heterocyclic moiety, and in addition to carbon atoms, has one or more, preferably one to four, heteroatoms as previously described. When used to refer to heteroatoms of a heterocycle, the term "nitrogen" includes substituted nitrogen. For example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, nitrogen can also be N (such as in 3,4-dihydro-2H-pyrrolyl), NH (such as in pyrrolidinyl).
[0123] The heterocycle can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any ring atom can be optionally substituted. Examples of the heterocycle include, but are not limited to, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepine, oxazepine, thiazepine, morpholinyl and quinuclidinyl.
[0124] The term "alkoxyalkyl" refers to an alkyl group as defined herein substituted with at least one, preferably one, two or three alkoxy groups as defined herein, including, for example, methoxymethyl and the like.
[0125] The term "alkylamino" refers to a -NHR group, wherein R is an alkyl group as defined herein. "C1-C6 alkylamino" refers to an alkylamino group as defined herein having 1 to 6 carbon atoms. A C1-C6 alkylamino group may be optionally substituted as defined above for alkylamino.
[0126] The term "hydrogen" refers to a -H group.
[0127] The term "hydroxy" refers to an -OH group.
[0128] The term "nitro" refers to a -NO2 group.
[0129] The term "cyano" refers to a -CN group.
[0130] The term "aminosulfonyl" refers to the -SO2NH2 group.
[0131] The term "amino" refers to a -NH2 group.
[0132] The term "trifluoromethyl" refers to a -CF3 group.
[0133] The terms "pharmaceutically acceptable" or "pharmaceutical" as used herein refer to those compounds, materials, compositions and / or dosage forms which are, within the scope of sound pharmaceutical judgment, suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic response, or other problems or complications, and are commensurate with a reasonable benefit / risk ratio.
[0134] As used herein, the term "pharmaceutically acceptable salt" refers to a derivative of a disclosed compound in which the parent compound is modified by preparing an acid or basic salt thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic base salts of basic groups, and salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. Salts derived from organic bases include, but are not limited to, primary, secondary, and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, dimethylethanolamine, 2-dimethylethanolamine, 2-diethylethanolamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, triethanolamine, trimethylamine, dicyclohexylamine. And alkaline or organic salts of acidic groups (e.g., carboxylic acids). Pharmaceutically acceptable salts include conventional inorganic salts of the parent compound formed from nontoxic inorganic or organic acids including those derived from inorganic acids, such as, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid; and salts prepared from organic acids, such as, for example, acetic acid, 2,2-dichloroacetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, palmitic acid, oleic acid, alginic acid, aspartic acid, lactic acid, lauric acid, malic acid, tartaric acid, citric acid, pyruvic acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, hippuric acid, isobutyric acid, pyroglutamic acid, salicylic acid, nicotinic acid, sulfanilic acid, benzoic acid, 4-acetamidobenzoic acid, 2-acetoxybenzoic acid, phenylacetic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid and isethionic acid, and the like.
[0135] Pharmaceutically acceptable salts of the present invention can be synthesized by the parent compound containing alkaline or acidic moieties by conventional chemical methods. Usually, these salts can be prepared by reacting the free acid or alkaline form of these compounds with a stoichiometric amount of suitable base or acid in water or an organic solvent or a mixture of the two.
[0136] The compounds of the present invention may exist in non-solvated and various solvated forms formed with pharmaceutically acceptable solvents such as water, ethanol, etc. In general, for the purposes of the present invention, solvated forms and non-solvated forms are considered to be equivalent. Pharmaceutically acceptable solvents further include isotope-substituted solvents, for example, D2O, etc. Crystallization is generally capable of producing solvates of the compounds of the present invention. The term "solvate" as used herein refers to a complex comprising a compound of the present invention and one or more pharmaceutically acceptable solvent molecules (including water). Therefore, various hydrates of the compounds of the present invention are also included in the term "solvate". That is, the present invention includes a mixture of non-solvated forms, solvated forms, and solvated forms in any proportion.
[0137] The compounds of the present invention or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may exist as enantiomers, diastereomers and other stereoisomeric forms, which may be defined as (R)- or (S)-, or as (D)- or (L)-amino acids from the perspective of absolute stereochemistry. The present invention includes all such possible isomers and their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)- or (D)- and (L)-isomers may be prepared by chiral synthesis or chiral practice, or by conventional techniques such as HPLC using chiral columns. Unless otherwise specified, when the compounds described herein contain olefinic double bonds or other geometric asymmetric centers, the compounds shall include E and Z geometric isomers. Likewise, all tautomers are also included.
[0138] Stereoisomers are compounds composed of the same atoms bound by the same bonds but with different three-dimensional structures, which are not interchangeable. The present invention includes various stereoisomers and mixtures thereof, including "enantiomers", which refer to two stereoisomers whose molecules are non-superimposable mirror images of each other.
[0139] The present invention includes all pharmaceutically acceptable isotope-labeled variants of the compound of formula (I). These isotope-labeled compounds have the same structure and molecular formula as the compound of formula (I), but one or more atoms therein are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number commonly found in nature. Examples of isotopes that can be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, fluorine, nitrogen and oxygen, such as D, 3 H. 11 C. 13 C. 14 C. 18 F. 13 N. 15 N. 15 O. 17 O and 18 O. Certain isotopically labeled variants of the compounds of the invention, for example, those incorporating radioactive isotopes such as 3 H and 14 The compounds of C can be used for the study of drug and / or substrate tissue distribution. 3 H and carbon 14 14C, because they are easy to prepare and detect. Further, substitution with heavier isotopes such as deuterium, i.e., D, can bring certain therapeutic advantages due to its stronger metabolic stability, such as an increase in half-life in vivo or a reduction in the required dosage, and is therefore particularly preferred in certain circumstances. The isotope-labeled compounds of formula (I) and their prodrugs of the present invention can generally be prepared by the process disclosed in the route map and / or the examples described in the present invention, using readily available isotope-labeled reagents to replace non-isotope-labeled reagents.
[0140] The term "co-crystal or co-crystallized salt" means a crystalline substance composed of two or more specific substances that are solid at room temperature, each of which has different physical properties (e.g., structure, melting point, heat of fusion, hygroscopicity, solubility and stability, etc.). Co-crystals or co-crystallized salts can be prepared according to co-crystallization methods known per se. Formula (I) of the present invention can be a pharmaceutically acceptable co-crystal or co-crystallized salt.
[0141] The term "prodrug" refers to a compound that undergoes chemical conversion by a metabolic process or a chemical process after administration to a subject to obtain a compound of formula (I) and / or a pharmaceutically acceptable salt and / or solvate thereof.
[0142] The term "composition" includes a product of the specified ingredients in the specified amounts, as well as a product obtained directly or indirectly by combining the specified ingredients in the specified amounts. The term, when related to a pharmaceutical composition, includes a product of active ingredients and inert ingredients constituting a carrier, as well as any product obtained directly or indirectly by the combination, complexation or aggregation of any two or more such ingredients, or by the separation of one or more such ingredients, or by other types of reactions or interactions of one or more such ingredients. Therefore, the pharmaceutical compositions of the present invention include any composition obtained by mixing a compound of the present invention with a pharmaceutically acceptable carrier.
[0143] As used herein, the term "pharmaceutical carrier, vehicle, diluent or excipient" is a medium generally accepted in the art for delivering a bioactive agent to an animal, especially a mammal. It includes, without limitation, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier. The pharmaceutical composition of the present invention can be formulated into a form that provides rapid, sustained or delayed release of the active ingredient after administration to a subject by methods known in the prior art. A detailed discussion of pharmaceutical carriers, vehicles, diluents or excipients is published in Remington's Pharmaceutical Sciences (Mack Publishing Company, current edition).
[0144] The term "therapeutically effective amount" refers to the effect and amount of the compound, composition or drug of the present invention, which is sufficient to effectively treat SCD1-mediated diseases or conditions in mammals, preferably humans, when administered to mammals, preferably humans, and can ① treat specific diseases, conditions or disorders; ② inhibit, alleviate, improve or eliminate one or more symptoms of specific diseases, conditions or disorders or complications caused by specific diseases, conditions or disorders; ③ prevent or delay the onset of one or more symptoms of specific diseases, conditions or disorders or complications caused by specific diseases, conditions or disorders. "Therapeutically effective amount" includes any one or more of the above effects ①-③.
[0145] The terms "mammal" and "subject" include warm-blooded animals, for example, rodents, cats, dogs, pigs, cows, sheep, horses, rabbits, monkeys, chimpanzees, and humans.
[0146] The definition of each symbol in formula (I) will be described in detail below.
[0147] In certain embodiments, the present invention provides compounds of formula (I):
[0148] (I)
[0149] or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer or racemate thereof;
[0150] in,
[0151] m and n are each independently 0 or 1;
[0152] X and Y together form a cyclopropyl, cyclobutyl or cyclopentyl group;
[0153] U and V together form a cyclopropyl, cyclobutyl or cyclopentyl group;
[0154] W is an oxygen atom;
[0155] Q is independently selected from aryl or heteroaryl;
[0156] R1 is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C3-C6 cycloalkyl, halogen, optionally halogenated C1-C6 alkyl, C1-C6 alkoxy, optionally halogenated C1-C6 alkoxy, C3-C6 cycloalkyloxy, optionally halogenated C3-C6 cycloalkyloxy;
[0157] R2 is independently selected from hydrogen, hydroxy, hydroxy-substituted C1-C6 alkyl, C1-C6 alkyl, C3-C6 cycloalkyl, halogen, optionally halogenated C1-C6 alkyl, C1-C6 alkoxy, optionally halogenated C1-C6 alkoxy, C3-C6 cycloalkyloxy, optionally halogenated C3-C6 cycloalkyloxy, alkoxyalkyl, nitro, cyano, aminosulfonyl, amino, C1-C6 alkylamino, -C(O)NH(R3);
[0158] R3 is independently selected from hydrogen or C1-C6 alkyl.
[0159] In certain embodiments, the present invention provides compounds of formula (I) having the following formula (Ia):
[0160] (Ia)
[0161] or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer, or racemate thereof;
[0162] in,
[0163] m is independently 0 or 1;
[0164] U and V together form a cyclopropyl, cyclobutyl or cyclopentyl group;
[0165] W is an oxygen atom;
[0166] Q is independently selected from aryl or heteroaryl;
[0167] R1 is independently selected from hydrogen, halogen, optionally halogenated C1-C6 alkyl;
[0168] R2 is independently selected from hydrogen, hydroxy, hydroxy-substituted C1-C6 alkyl, C1-C6 alkyl, C3-C6 cycloalkyl, halogen, optionally halogenated C1-C6 alkyl, C1-C6 alkoxy, optionally halogenated C1-C6 alkoxy, C3-C6 cycloalkyloxy, optionally halogenated C3-C6 cycloalkyloxy, alkoxyalkyl, nitro, cyano, aminosulfonyl, amino, C1-C6 alkylamino, -C(O)NH(R3);
[0169] R3 is independently selected from hydrogen or C1-C6 alkyl.
[0170] In certain embodiments, the present invention provides compounds of formula (I) having the following formula (Ib):
[0171] (Ib)
[0172] or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer or racemate thereof;
[0173] in,
[0174] U and V together form a cyclopropyl, cyclobutyl or cyclopentyl group;
[0175] Q is independently selected from aryl or heteroaryl;
[0176] R1 is independently selected from hydrogen, halogen, optionally halogenated C1-C6 alkyl;
[0177] R2 is independently selected from hydrogen, hydroxy, hydroxy-substituted C1-C6 alkyl, C1-C6 alkyl, C3-C6 cycloalkyl, halogen, optionally halogenated C1-C6 alkyl, C1-C6 alkoxy, optionally halogenated C1-C6 alkoxy, C3-C6 cycloalkyloxy, optionally halogenated C3-C6 cycloalkyloxy, alkoxyalkyl, nitro, cyano, aminosulfonyl, amino, C1-C6 alkylamino, -C(O)NH(R3);
[0178] R3 is independently selected from hydrogen or C1-C6 alkyl.
[0179] In certain embodiments, the present invention provides a compound of formula (I) having the following formula (Ic):
[0180] (Ic)
[0181] or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer or racemate thereof;
[0182] in,
[0183] Q is independently selected from aryl or heteroaryl;
[0184] R1 is independently selected from trifluoromethyl or halogen;
[0185] R2 is independently selected from hydrogen, hydroxy, hydroxy-substituted C1-C6 alkyl, halogen, -C(O)NH(R3);
[0186] R3 is independently selected from hydrogen or C1-C6 alkyl.
[0187] In certain embodiments, the present invention provides compounds of formula (Ic), wherein R1 is trifluoromethyl and Q is independently selected from
[0188] , ;
[0189] R2 is independently selected from hydroxy-substituted C1-C6 alkyl, halogen, -C(O)NH(R3);
[0190] R3 is independently selected from hydrogen or C1-C6 alkyl.
[0191] In certain embodiments, the present invention provides a compound of formula (I) having the following formula (Id):
[0192] (Id)
[0193] or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer or racemate thereof;
[0194] in,
[0195] R1 is independently selected from trifluoromethyl or halogen;
[0196] R2 is independently selected from C1-C6 alkyl substituted with hydroxy, C1-C6 alkyl.
[0197] In certain embodiments, the present invention provides a compound of formula (I) having the following formula (Ie):
[0198] (Ie)
[0199] or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer or racemate thereof;
[0200] in,
[0201] R1 is independently selected from trifluoromethyl or halogen;
[0202] R2 is independently selected from C1-C6 alkyl substituted with hydroxyl;
[0203] In certain embodiments, the present invention provides the following compounds:
[0204] 1) ,
[0205] 2) ,
[0206] 3) ,
[0207] 4) ,
[0208] 5) or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
[0209] The present invention relates to compounds, pharmaceutical compositions and methods of using the compounds and pharmaceutical compositions to treat and / or prevent diseases mediated by SCD1, particularly hSCD1, including lipid disorders, metabolic syndrome, weight disorders, skin diseases, fatty liver disease, diabetes and cancer by administering to a subject in need of such treatment a therapeutically effective amount of an SCD1 inhibitor.
[0210] The compounds of the present invention are stearoyl-CoA Δ-9 desaturase 1 inhibitors and can be used to treat diseases and conditions in a subject, including all of the diseases and conditions in the subject caused by abnormal stearoyl-CoA Δ-9 desaturase 1 biological activity or which can be treated and / or prevented by regulating the biological activity of stearoyl-CoA Δ-9 desaturase 1.
[0211] SCD1 mediated disorders, diseases or conditions include, but are not limited to, the following diseases or conditions or diseases or conditions associated with lipid disorders, metabolic syndrome, weight disorders, skin diseases, fatty liver disease, diabetes and cancer.
[0212] SCD1-mediated disorders, diseases or conditions include lipid disorders, including but not limited to dyslipidemia, hyperlipidemia, hypertriglyceridemia, atherosclerosis, hypercholesterolemia, low high-density lipoprotein and high low-density lipoprotein. In particular, dyslipidemia is characterized by one or more of the following factors, including but not limited to high triglycerides, low high-density lipoprotein concentration, low apolipoprotein A lipoprotein concentration, high low-density lipoprotein cholesterol concentration, and high apolipoprotein B lipoprotein concentration.
[0213] SCD1-mediated disorders, diseases or conditions also include metabolic syndrome, which includes a combination of diabetes, impaired glucose tolerance, insulin resistance, hypertension, obesity, increased abdominal girth, high triglycerides, low high-density lipoprotein, hyperuricemia, microalbuminuria and / or a thrombotic, hypercoagulable and prothrombotic state.
[0214] SCD1 mediated disorders, diseases or conditions also include weight disorders, including but not limited to obesity, overweight, cachexia and anorexia.
[0215] SCD1 mediated disorders, diseases or conditions also include skin disorders including, but not limited to, eczema, acne, rosacea, seborrheic dermatitis, keloid scarring or prevention.
[0216] SCD1 mediated disorders, diseases or conditions also include fatty liver disease, including but not limited to fatty liver, fatty liver degeneration, hepatitis, nonalcoholic hepatitis, nonalcoholic steatohepatitis, alcoholic hepatitis, acute fatty liver, fatty liver of pregnancy, drug-induced hepatitis.
[0217] SCD1 mediated disorders, diseases or conditions also include diabetes, including but not limited to type II diabetes, hyperglycemia, insulin resistance, impaired glucose tolerance.
[0218] SCD1-mediated disorders, diseases or conditions also include those associated with neoplastic cell proliferation, including but not limited to benign or malignant tumors, cancer, neoplasia, metastasis, carcinogenesis.
[0219] In certain embodiments, the present invention provides methods of treating or preventing a disorder, disease or condition associated with the biological activity of SCD1 in a subject in need thereof by administering a compound or pharmaceutical composition of the present invention.
[0220] In certain embodiments, the present invention provides methods for treating and / or preventing lipid disorders, metabolic syndrome, weight disorders, skin diseases, fatty liver disease, diabetes, and cancer by administering a compound or pharmaceutical composition of the present invention.
[0221] In certain embodiments, the present invention provides methods for treating and / or preventing dyslipidemia, hyperlipidemia, hypertriglyceridemia, atherosclerosis, hypercholesterolemia, low high-density lipoprotein, and high low-density lipoprotein by administering a compound or pharmaceutical composition of the present invention.
[0222] In certain embodiments, the present invention provides methods for treating and / or preventing a combination of dyslipidemia, diabetes, impaired glucose tolerance, obesity, insulin resistance, hypertension, hypertriglyceridemia, increased abdominal circumference, low high-density lipoprotein, microalbuminemia, hyperuricemia and / or hypercoagulability by administering a compound or pharmaceutical composition of the present invention.
[0223] In certain embodiments, the present invention provides methods for treating and / or preventing obesity, overweight, cachexia and anorexia by administering a compound or pharmaceutical composition of the present invention.
[0224] In certain embodiments, the present invention provides methods for treating and / or preventing eczema, acne, rosacea, seborrheic dermatitis, oily skin, rosacea, and keloid scarring or preventing or other skin conditions caused by lipid imbalance by administering a compound or pharmaceutical composition of the present invention.
[0225] In certain embodiments, the present invention provides methods for treating and / or preventing fatty liver, fatty liver degeneration, alcoholic steatohepatitis, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic hepatitis, acute fatty liver, acute liver injury and cirrhosis by administering a compound or pharmaceutical composition of the present invention.
[0226] In certain embodiments, the present invention provides methods for treating and / or preventing renal cell carcinoma, liver cancer, bladder cancer, breast cancer, lung cancer, prostate cancer, ovarian cancer, colon cancer, melanoma, pancreatic cancer, and thyroid cancer by administering a compound or pharmaceutical composition of the present invention.
[0227] According to an embodiment of the present invention, any assay known in the art, for example, the assay described in the human subcutaneous preadipocyte assay in the pharmacological experiment herein, can be used to determine the inhibitory activity of SCD1. Model systems for compound evaluation can include, but are not limited to, liver microsomes used, from mice maintained on a high carbohydrate diet or from human donors using primary cell lines, for example, human subcutaneous preadipocytes, to detect changes in the content of triglycerides in human cells.
[0228] In an embodiment of the present invention, when the change in triglyceride content is measured in human subcutaneous preadipocytes as described herein, the compound of the present invention has an IC of less than 1000 μM, or less than 100 μM, or less than 10 μM, or less than 1 μM, or less than 0.5 μM. 50 value.
[0229] The present invention also relates to pharmaceutical compositions containing the compounds of the present invention. In certain embodiments, the present invention relates to pharmaceutical compositions of compounds and pharmaceutical carriers, vehicles, diluents or excipients. The compounds or compositions of the present invention can be prepared in any suitable dosage form, including oral dosage forms, for example, in the form of tablets, capsules, granules or liquid preparations (including syrups); topical administration forms, for example, in the form of solutions, gels, pastes, suspensions, ointments, sprays, creams, or lotions; parenteral, for example, by subcutaneous, intravenous, intramuscular, intrasternal injection or infusion techniques (for example, in the form of sterile injectable aqueous or non-aqueous solutions or suspensions); nasal administration forms, for example, by inhalation sprays or aerosols; rectal and / or vaginal administration, for example, in the form of suppositories; sublingual administration; buccal administration, or liposomes. A unit dose formulation containing a non-toxic pharmaceutically acceptable carrier or diluent can be administered. The compound can be administered in a form suitable for immediate release or extended release. Immediate release or extended release can be achieved using suitable pharmaceutical compositions or, in the case of extended release, using, for example, subcutaneous injections or osmotic pump devices. The compounds of formula (I) can be administered in any form suitable for the disease state to be treated, which may depend on the need for site-specific treatment or the amount of drug to be delivered. Although other modes of delivery are contemplated, the present invention prefers local administration forms to treat the disease or condition.
[0230] Preferred skin administration forms are specifically described (for topical administration, the pharmaceutical composition can be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays and drops suitable for application to the skin or nose. Topical administration can also include transdermal administration via means such as transdermal patches. Aerosol preparations suitable for administration via inhalation can also be prepared. For example, the compounds of the present invention can be administered by inhalation in the form of a powder (e.g., micronized) or atomized solution or suspension. Aerosol preparations can be placed into pressurized acceptable propellants.)
[0231] If a topical formulation is used, the compounds of the invention may be used with or without a transdermal penetration enhancer. Any suitable enhancer known in the art may be used. The enhancer may be used at any suitable concentration, for example, less than about 50% (w / v), less than about 20%, less than about 10%, less than about 5%, or less than about 1%.
[0232] Various solid oral dosage forms can be used to administer the compounds of the present invention, including solid forms of tablets, soft gelatin capsules, capsules, caplets, granules, lozenges, and bulk powders. The compounds of the present invention can be administered alone or in combination with various pharmaceutically acceptable carriers, diluents (e.g., sucrose, mannitol, lactose, starch, etc.) and excipients known in the art, including, but not limited to, suspending agents, solubilizers, buffers, binders, disintegrants, preservatives, colorants, flavoring agents, lubricants, and the like.
[0233] Various liquid oral dosage forms can also be used to administer the compounds of the present invention, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups and elixirs. These dosage forms may also contain suitable inert diluents known in the art (e.g., water) and suitable excipients known in the art, such as preservatives, wetting agents, additives, flavoring agents, and excipients for emulsifying and / or suspending the compounds of the present invention. The compounds of the present invention may be administered in other formulations (e.g., intravenously injected in an isotonic sterile solution).
[0234] Suppositories for rectal administration of the compounds of the present invention can be prepared by mixing the compounds with suitable non-irritating excipients, for example, cocoa butter, synthetic glycerides or polyethylene glycols, which are solid at room temperature but liquefy and / or dissolve in the rectal cavity to release the drug. Preparations for vaginal administration can be in the form of vaginal suppositories, emulsions, gels, pastes, foams or sprays containing suitable carriers known in the art in addition to the active ingredient.
[0235] Typically, the therapeutically effective amount of the compounds of the present invention can be determined by those skilled in the art, and for mammals, the preferred dosage range is 0.001 mg / kg to 10000 mg / kg, including, for example, 0.5 mg / kg, 1.0 mg / kg, 2.0 mg / kg, 5 mg / kg, 10 mg / kg, 20 mg / kg, 100 mg / kg, but dosages beyond this range are still acceptable. The dosage regimen can be once or twice a day, or the number of administrations can be increased or decreased. It should be understood that the specific dosage level and frequency of administration for any particular subject may vary and should depend on various factors, including the activity of the specific compound used, the metabolic stability and duration of action of the compound, the species, age, weight, general health, sex and diet of the subject, mode and time of administration, excretion rate, drug combination and severity of a particular disease.
[0236] Those skilled in the art are also familiar with how to determine the method of administration (topical administration, oral administration, injection, inhalation, etc.), dosage form, appropriate pharmaceutical excipients and other matters related to delivering the drug to the subject in need of treatment.
[0237] The term "combination therapy" as used in this application refers to a dosage regimen in which a compound of formula (I) and a second therapeutic agent, usually with a different mechanism of action, are used together to improve the therapeutic effect. It is understood that "combination therapy" is not limited by route of administration and may refer to simultaneous administration, administration at different times of the day, or even administration on different days. These compounds may be administered separately or may be combined in a single formulation (fixed combination) for administration.
[0238] In order to enhance the effect of the compounds of the present invention or reduce the dosage of the compounds, the compounds of the present invention can be used in combination with the following drugs. In certain embodiments, the drugs include: diabetes therapeutic agents, diabetic complication therapeutic agents, anti-hyperlipidemia therapeutic agents, antihypertensive agents, weight loss agents, antithrombotic agents, etc.
[0239] As therapeutic agents for diabetes, insulin preparations (e.g., animal insulin preparations extracted from the pancreas of cows or pigs, human insulin preparations synthesized by genetic engineering using Escherichia coli or yeast, zinc insulin, protamine zinc insulin, insulin fragments or derivatives, oral insulin preparations), insulin sensitizers (e.g., pioglitazone or its salts, rosiglitazone or its salts), α-glucosidase inhibitors (e.g., voglibose, acarbose, miglitol), biguanides (e.g., metformin), insulin secretion promoters can be used. (e.g., sulfonylurea secretagogues (e.g., glibenclamide, gliclazide, chlorpropamide, tolbutamide, glimepiride, glipizide), non-sulfonylurea secretagogues (e.g., repaglinide, mitiglinide, nateglinide), dipeptidyl peptidase IV inhibitors (e.g., linagliptin, sitagliptin, alogliptin, saxagliptin), GLP-1 receptor agonists (e.g., liraglutide, exenatide, lixisenatide, semaglutide, dulaglutide)), sodium-glucose cotransporter 2 inhibitors (e.g., dapagliflozin, empagliflozin).
[0240] As therapeutic agents for diabetic complications, there can be used agents including, but not limited to, aldose reductase inhibitors (eg, epalrestat), GABA receptor agonists (eg, gabapentin, pregabalin), cerebral vasodilators (eg, tiapride, mexiletine), and the like.
[0241] As therapeutic agents for hyperlipidemia, there can be used agents including, but not limited to, HMG-GoA reductase inhibitors (e.g., pravastatin, simvastatin, lovastatin, atorvastatin, pitavastatin), fibrate compounds (e.g., bezafibrate, fenofibrate, ciprofibrate), and anion exchange resins (e.g., cholestyramine, probucol).
[0242] As antihypertensive agents, there can be used drugs including, but not limited to, angiotensin converting enzyme inhibitors (e.g., captopril, enalapril, delapril), angiotensin II antagonists (e.g., candesartan, losartan, valsartan, irbesartan, azilsartan medoxomil), calcium antagonists (e.g., nifedipine, amlodipine), beta-adrenaline receptor antagonists (e.g., metoprolol, atenolol, propranolol, pindolol, clonidine).
[0243] As weight loss agents, there can be used agents including, but not limited to, monoamine uptake inhibitors (e.g., phentermine), GABA modulators (e.g., topiramate), pancreatic lipase inhibitors (e.g., orlistat), GLP-1 receptor agonists (e.g., liraglutide, semaglutide, telpotide).
[0244] As antithrombotic agents, there can be used agents including, but not limited to, heparin (e.g., heparin sodium, heparin calcium, enoxaparin sodium), warfarin, thrombin inhibitors (e.g., argatroban, dabigatran), thrombolytic drugs (e.g., urokinase, alteplase, natalizumab), platelet aggregation inhibitors (e.g., clopidogrel, ticagrelor), and FXa inhibitors (e.g., apixaban, rivaroxaban).
[0245] In order to enhance or complement the desired therapeutic effect, or to minimize potential side effects, in certain embodiments, the compounds of the present invention can be used with drugs including but not limited to topical retinoids (e.g., all-trans retinoic acid, isotretinoin, adapalene, tazarotene), antibacterial drugs (e.g., benzoyl peroxide), antibiotics (e.g., erythromycin, lincomycin, clindamycin, chloramphenicol, clomiphene clindamycin, doxycycline, minocycline), anti-androgen therapy (e.g., estrogen, progesterone, spironolactone, insulin sensitizers).
[0246] The compounds of the present invention can be used in combination with other drugs. In certain embodiments, the compounds of the present invention can be used together with drugs such as hormone therapeutic agents, chemotherapeutic agents, immunotherapeutic agents, drugs that inhibit the effects of cell growth factors and their receptors, and the like.
[0247] As the “hormone therapeutic agent”, for example, diethylstilbestrol, chlorethoxyquin, medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, cyproterone acetate, ormeloxifene, levomeloxifen, antiestrogens (e.g., tamoxifen citrate), melastane, aminoglutethimide, LH-RH agonists (e.g., goserelin acetate, buserelin, leuprolide acetate), droloxifene, ethinyl estradiol sulfonate, aromatase inhibitors (e.g., fadrozole hydrochloride, anastrozole, letrozole), antiandrogens (e.g., flutamide, bicalutamide, nilutamide, enzalutamide), 5α-reductase inhibitors (e.g., finasteride, epristeride, dutasteride), adrenocortical hormone drugs (e.g., dexamethasone, prednisolone, betamethasone, triamcinolone acetonide), androgen synthesis inhibitors (e.g., abiraterone), thyroid hormones, and DDS (delivery system) preparations thereof can be used.
[0248] Examples of "chemotherapeutic agents" that can be used include alkylating agents, metabolic antagonists, anticancer antibiotics, plant-derived anticancer agents.
[0249] Alkylating agents that may be used include, but are not limited to, nitrogen mustard, chlorambucil, cyclophosphamide, ifosfamide, dacarbazine, ranimustine, estramustine sodium phosphate, carmustine, carboplatin, cisplatin, miplatin, nedaplatin, oxaliplatin, fotemustine, bendamustine, temozolomide, adolesin, and DDS formulations thereof.
[0250] Metabolic antagonists that can be used include, but are not limited to, mercaptopurine, 6-mercaptopurine ribonucleotides, methotrexate, pemetrezole, cytarabine, aminopterin, 5-FU drugs (such as fluorouracil, capecitabine, tegafur, galocitabine), nelarabine, calcium folinate, calcium levulinate, pentostatin and its DDS preparations.
[0251] Anticancer antibiotics that can be used include, but are not limited to, actinomycin D, mitomycin C, bleomycin hydrochloride, bleomycin sulfate, daunorubicin hydrochloride, doxorubicin hydrochloride, epirubicin hydrochloride, mitoxantrone hydrochloride, and DDS preparations thereof.
[0252] Plant-derived anticancer agents that may be used include, but are not limited to, etoposide, vinblastine sulfate, paclitaxel, docetaxel, cabazitaxel, vinorelbine, and DDS formulations thereof.
[0253] Immune preparations that can be used include, but are not limited to, Versicolor polysaccharide K, mushroom polysaccharides, ubenimex, interferon, interleukin, macrophage colony-stimulating factor, granulocyte colony-stimulating factor, erythropoietin, BCG vaccine, anti-CTLA4 antibodies (e.g., ipilimumab), anti-PD-1 antibodies (e.g., nivolumab, pembrolizumab), and anti-PD-L1 antibodies.
[0254] The cell growth factor in the drug that inhibits cell growth factor and its receptor can be any substance that can promote cell growth. Its typical example includes such a factor that has a molecular weight of 20,000 or less peptides, and produces an effect at a low concentration by binding to its receptor. Specific examples of cell growth factors that can be used include, but are not limited to, ① EGF (epidermal growth factor) or substances with substantially the same activity as EGF such as TGFα, ② insulin or substances with substantially the same activity as insulin such as insulin, IGF-1 (insulin-like growth factor-1), IGF-2, ③ FGF (fibroblast growth factor) or substances with substantially the same activity as FGF such as acidic FGF, basic FGF, KGF (keratinocyte growth factor), FGF-10, and ④ other cell growth factors such as CSF (clone stimulating factor), IL-2, NGF (nerve growth factor), PDGF (platelet growth factor), TGFβ (transforming growth factor β), HGF (hepatocyte growth factor), VEGF (vascular endothelial growth factor), angiogenin.
[0255] The receptor of cell growth factor can be any receptor that can be combined with any of the above-mentioned cell growth factors. The example of receptor that can be used includes but is not limited to EGF receptor, insulin receptor, IGF receptor-1, IGF receptor-2, FGF receptor-1 or FGF receptor-2, VEGF receptor, angiogenin receptor, PDGF receptor etc.
[0256] Drugs that can be used to inhibit cell growth factors and their receptors include, but are not limited to, EGF inhibitors, TGFα inhibitors, insulin inhibitors, FGF inhibitors, CSF inhibitors, EPO inhibitors, IL-2 inhibitors, PDGF inhibitors, TGFβ inhibitors, HGF inhibitors, VEGF inhibitors, EGFR inhibitors, HER2 inhibitors, insulin receptor inhibitors, IGF-1 receptor inhibitors, IGF-2 receptor inhibitors, FGFR-1 inhibitors, FGFR-2 inhibitors, FGFR-3 inhibitors, FGFR-4 inhibitors, VEGFR inhibitors, Tie-2 inhibitors, PDGFR inhibitors, Abl inhibitors, Raf inhibitors, FLT3 inhibitors, c-Kit inhibitors, Src inhibitors, PKC inhibitors, Smo inhibitors, ALK inhibitors, ROR1 inhibitors, Trk inhibitors, Ret inhibitors, mTOR inhibitors, Aurora inhibitors, PLK inhibitors, MEK (MEK1 / MEK2) inhibitors, MET inhibitors, CDK inhibitors, Akt inhibitors, Erk inhibitors, PI3K inhibitors, and the like. More specific examples of drugs that can be used include, but are not limited to, anti-VEGF antibodies (e.g., bevacizumab), anti-HER2 antibodies (e.g., trastuzumab, pertuzumab), anti-EGFR antibodies (e.g., cetuximab, nimotuzumab), anti-HGF antibodies, imatinib, gefitinib, sorafenib, sunitinib, dasatinib, lapatinib, ibrutinib, cabozantinib, crizotinib, axitinib, vandetanib, sirolimus, everolimus, afatinib, dabrafenib, trametinib, etc.
[0257] In addition to the above drugs, L-asparaginase, L-arginase, arginine deiminase, acetoglucuronolide, procarbazine hydrochloride, protoporphyrin-cobalt complex salt, mercurohematoporphyrin-sodium, topoisomerase I inhibitors (e.g., irinotecan, topotecan), topoisomerase II inhibitors (e.g., sobuzoxane), differentiation inducers (e.g., vitamin D), other angiogenesis inhibitors (e.g., fumagillin, COX-2 inhibitors), α-blockers (e.g., tamsulosin hydrochloride), bisphosphonates (e.g., pamidronate, zoledronate), lenalidomide, pomalidomide, decitabine, proteasome inhibitors (e.g., bortezomib, carfilzomib, ixazomib), PARP inhibitors (e.g., olaparib, niraparib), anti-tumor antibodies such as anti-CD20 antibodies (e.g., rituximab), etc., antibody-drug combinations (e.g., velidomide), etc., can also be used as combination drugs. Preparation method of the compound of the present invention
[0258] Example
[0259] Compound Implementation Method 1
[0260]
[0261] The starting materials of the above reaction schemes are commercially available or prepared according to methods known to those skilled in the art, or prepared using the methods disclosed herein. Generally, the compounds of the invention in the above reaction schemes are prepared as follows:
[0262] A series of compounds of formula (Ia) are prepared by the method shown in Compound Implementation Example 1. R-configured alcohol hydroxy compound 101 is reacted with a nucleophilic agent R1-substituted phenol 102 in the presence of, but not limited to, diisopropyl azodicarboxylate and triphenylphosphine at a suitable temperature, such as ambient temperature, to obtain S-configured compound 103 through Misunobu reaction. R1-substituted phenol 102 is a compound known in the art and can be obtained through commercial routes. Compound 103 can be deprotected from the tert-butyloxycarbonyl group in the presence of, but not limited to, an acid such as TFA in a solvent such as, but not limited to, DCM at a suitable temperature, such as ambient temperature, to obtain product 104. In, but not limited to N, N -dimethylformamide solvent, in the presence of an organic base such as N, N- In the presence of diisopropylethylamine, a coupling agent such as but not limited to HATU, TBTU, etc. is used for condensation to obtain a series of compounds of formula (Ia) through coupling reaction.
[0263] Typically, the compounds of the present invention are synthesized according to the general operations described in Embodiment 1, wherein m is each independently 0 or 1, U and V together form a cyclopropyl, cyclobutyl or cyclopentyl group, W is an oxygen atom, Q is independently selected from an aryl or heteroaryl group, and R1 and R2 correspond to suitable substituents that can obtain the compounds of the present invention.
[0264] Compound Implementation Method 2
[0265]
[0266] The starting materials of the above reaction schemes are commercially available or prepared according to methods known to those skilled in the art, or prepared using the methods disclosed herein. Generally, the compounds of the invention in the above reaction schemes are prepared as follows:
[0267] A series of compounds of formula (Ie) are prepared by the method shown in Embodiment 2 of the compound (wherein R1 and R2 correspond to suitable substituents that can obtain the compounds of the present invention). In a solvent such as but not limited to DMF, in the presence of a base such as imidazole, the hydroxyl group is protected by using, for example, TBSCl to obtain compound 107. In a solvent such as but not limited to THF, in the presence of a base such as but not limited to n-BuLi, at a suitable temperature such as -10°C, the amine group is protected by benzyl bromide to obtain compound 108. In the presence of titanium (II) such as but not limited to tetraisopropoxytitanium, the amide compound 108 is reacted with the Grignard reagent ethylmagnesium bromide at a suitable temperature such as -70°C to obtain the spirocyclic compound 109. In a THF solvent, TBAF is used to remove the silyl ether protection to obtain compound 110. The R-configured alcohol hydroxyl compound 110 is reacted with the nucleophilic reagent R1-substituted phenol 102 in the presence of, for example, but not limited to DIAD and PPh3 at a suitable temperature such as ambient temperature to obtain the S-configured compound 111. R1-substituted phenol 102 is a known compound in the art and can be obtained through commercial routes. Compound 111 can be debenzylated in a DCE solution, such as but not limited to, in the presence of 1-chloroethyl chloroformate, under nitrogen protection, at a suitable temperature such as 60°C to obtain product 104. In a solvent such as but not limited to DMF, in the presence of an organic base such as DIEA, condensation is carried out using a coupling agent such as but not limited to HATU to obtain a series of compounds of formula (Ie) through coupling reaction.
[0268] Although any person skilled in the art can prepare the compounds of this invention according to the above-mentioned disclosed general technology, for convenience, more detailed synthetic techniques of the compounds of this invention are provided elsewhere in this specification. In addition, all reagents and reaction conditions adopted in the synthesis are all known to those skilled in the art and can be obtained from normal commercial sources.
[0269] In the examples given, the phrase "drying and concentrating" generally refers to drying the solution in an organic solvent over sodium sulfate or magnesium sulfate, followed by filtering and removing the solvent from the filtrate (generally under reduced pressure and at a temperature appropriate to the stability of the material prepared). Chemical names were determined using ChemDraw professional version 16.0 (CambridgeSoft).
[0270] The following abbreviations are used:
[0271] Saturated salt solution = saturated sodium chloride solution
[0272] DCE = dichloroethane
[0273] DCM = dichloromethane
[0274] DIAD = diisopropyl azodicarboxylate
[0275] DIEA = N, N- Diisopropylethylamine
[0276] DMAP = 4-( N, N -dimethylamino)pyridine
[0277] DMF = N, N- dimethylformamide
[0278] DMSO = dimethyl sulfoxide
[0279] HATU = 2-(7-Azobenzotriazole-1-yl)- N, N, N', N' -Tetramethyluronium hexafluorophosphate
[0280] NaH = Sodium hydride
[0281] NaHCO3(aq) = saturated sodium bicarbonate solution
[0282] n-BuLi = n-Butyllithium
[0283] PPh3 = triphenylphosphine
[0284] rt = ambient room temperature (usually about 20-25°C)
[0285] TBAF = Tetrabutylammonium fluoride
[0286] TBSCl = tert-Butyldimethylsilyl chloride
[0287] TFA = trifluoroacetic acid
[0288] THF = Tetrahydrofuran
[0289] TBTU = O-Benzotriazole- N ,N, N', N' -Tetramethyluronium tetrafluoroborate
[0290] Specific compound preparation implementation plan
[0291] The following examples are used to further illustrate the present invention, but they are not intended to limit the present invention in any way.
[0292] Examples 1-4 were prepared from compound embodiment 1.
[0293] Example 1
[0294]
[0295] Example 1: S)-2-(4-(hydroxymethylphenoxy)-1-(7-(2-trifluoromethylphenoxy)-5-azaspiro[2.4]heptane-5-yl)ethan-1-one
[0296] Step 1: S )-tert-Butyl 7-(2-(trifluoromethyl)phenoxy)-5-azaspiro[2.4]heptane-5-carboxylate
[0297] Compound 1 (1.65 g, 7.74 mmol), o-trifluoromethylphenol (1.32 g, 8.13 mmol) and PPh3 (2.44 g, 9.29 mmol) were dissolved in dry THF solution (100 mL), DIAD (1.88 g, 9.29 mmol) was added under nitrogen protection, and the mixture was reacted at 40°C for 16 hours. The mixture was extracted with ethyl acetate (100 mL), washed with water (50 mL) and saturated brine (50 mL) in sequence, the organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and flash column chromatography (petroleum ether: ethyl acetate = 10:1) was performed to obtain a crude yellow oil 3 (1.15 g).
[0298] Step 2: S )-7-(2-(trifluoromethyl)phenoxy)5-azaspiro[2.4]heptane
[0299] Compound 3 (1.15 g, crude product) was dissolved in DCM solution (30 mL) and trifluoroacetic acid (6 mL) was added to react at room temperature for 2 hours. The reaction was concentrated under reduced pressure to obtain a crude product, which was purified by flash column chromatography (dichloromethane: methanol = 5:1) to obtain a yellow oil 4 (1.1 g), with a total yield of 40.0% for two steps.
[0300] 1 H NMR (Bruker AVANCE II, 400 MHz, CDCl3): δ ppm 10.11 (s, 1H), 7.57(d, J = 7.6 Hz, 1H), 7.48 – 7.44 (m, 1H), 7.07 – 7.03 (m, 1H), 6.80 (d, J = 8.0Hz, 1H), 4.48 (s, 1H), 3.89 (dd, J = 5.6, 13.2 Hz, 1H), 3.66 (d, J = 11.6 Hz,1H), 3.50 (d, J = 13.2 Hz, 1H), 3.06 (d, J= 11.2 Hz, 1H), 0.87 – 0.80 (m, 4H).
[0301] LCMS: Rt = 0.961 min, MS (ESI) m / z = 258.1 [M+H] + .
[0302] Step 3: S )-2-(4-(hydroxymethylphenoxy)-1-(7-(2-trifluoromethylphenoxy)-5-azaspiro[2.4]heptane-5-yl)ethan-1-one
[0303] Compound 4 (560 mg, 2.16 mmol) was dissolved in DMF solution (10 mL), and 4-hydroxymethylphenoxyacetic acid (474.0 mg, 2.60 mmol), HATU (823.9 mg, 2.16 mmol) and DIEA (839.1 mg, 6.50 mmol) were added respectively, and the mixture was reacted at room temperature for 16 hours. 10 mL of aqueous solution was added for dilution, and the mixture was extracted with ethyl acetate (3×10 mL), washed with saturated brine (3×10 mL), dried with anhydrous Na2SO4, concentrated under reduced pressure, and prepared by high performance liquid chromatography (Gemini-C18 column, 5 µ silica gel, diameter 21.2 mm, length 150 mm, mobile phase: water (containing 0.05% TFA) and acetonitrile 15-70% gradient elution), to obtain a light-colored oil PCD-102-220214-017 (51 mg, 5.5%).
[0304] 1 H NMR (temperature 80°C, Bruker AVANCE II, 400 MHz, DMSO- d 6): δ ppm 7.58 -7.53 (m, 2H), 7.28 - 7.14 (m, 3H), 7.10 (t, J = 7.5 Hz, 1H), 6.83–6.76 (m,2H), 4.84 - 4.56 (m, 4H), 4.41 (d, J = 5.3 Hz, 2H), 4.12–3.85 (m, 1H), 3.81 -3.71 (m, 1H), 3.67 - 3.61 (m, 1H), 3.43 - 3.17 (m, 1H), 0.95 - 0.65 (m, 4H).
[0305] HPLC: Rt = 4.89 min, purity: 100% (214 nm and 254 nm).
[0306] LCMS: Rt = 1.01 min, MS (ESI) m / z = 664.1 [M+H] + .
[0307] Example 2
[0308]
[0309] Example 2: S )-N-methyl-3-(2-oxo-2-(7-(2-(trifluoromethyl)phenoxy)-5-azaspiro[2.4]hexan-5-yl)ethoxy)pyrazine-2-carboxamide
[0310] Step 1: 3-Chloro- N -Methylpyrazine-2-carboxamide
[0311] Compound 6 (1.5 g, 9.49 mmol) was dissolved in dichloromethane solution (20 mL), oxalyl chloride (2.4 g, 19.06 mmol) and DMF (1 drop) were added, and the mixture was reacted at room temperature for 1 hour. After concentration, dichloromethane solution (20 mL), DIEA (6.1 g, 47.23 mmol) and methylamine hydrochloride (830.4 mg, 12.3 mmol) were added in sequence, and the mixture was reacted at room temperature for 2 hours. After concentration, the mixture was diluted with aqueous solution (50 mL) and extracted with ethyl acetate (2 × 100 mL). The organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and flash column chromatography (petroleum ether: ethyl acetate = 2:1) was performed to obtain yellow solid powder 7 (1.2 g, 74.1%).
[0312] 1 H NMR (Bruker AVANCE II, 400 MHz, CDCl3): δ ppm 8.53 (d, J = 2.4 Hz,1H), 8.48 (d, J = 2.4 Hz, 1H), 7.58 (br. s, 1H), 3.04 (d, J = 5.2 Hz, 3H).
[0313] LCMS: Rt = 0.671 min, MS (ESI) m / z = 172.0 [M+H] + .
[0314] Step 2: tert-Butyl 2-((3-(methylcarbamoyl)pyrazin-2-yl)oxy)acetate
[0315] NaH (364 mg, 9.09 mmol) was dissolved in dry DMF solution (10 mL). Tert-butyl 2-glycolate (1.1 g, 8.33 mol) was added at 0°C under nitrogen protection. After reacting at 0°C for 1 hour, a DMF solution (10 mL) of compound 7 (1.2 g, 7.02 mmol) was added and reacted at 0°C for 15 hours. The reaction was quenched with saturated NH4Cl solution (10 mL), extracted with ethyl acetate (100 mL), and washed with water (2 × 30 mL) and saturated brine (30 mL). The organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and flash column chromatography (petroleum ether: ethyl acetate = 1:2) was performed to obtain yellow solid powder 8 (1.3 g, 69.5%).
[0316] 1 H NMR (Bruker AVANCE II, 400 MHz, CDCl3): δ ppm 8.28 (d, J = 2.4 Hz,1H), 8.20 (d, J = 2.4 Hz, 1H), 7.78 (br. s, 1H), 4.96 (s, 2H), 3.05 (d, J = 5.2 Hz, 3H), 1.46 (s, 9H).
[0317] LCMS: Rt = 1.074 min, MS (ESI) m / z = 268.1 [M+H] + .
[0318] Step 3: 2-((3-(methylcarbamoyl)pyrazin-2-yl)oxy)acetic acid
[0319] Compound 8 (1.2 g, 4.49 mmol) was dissolved in dichloromethane solution (20 mL) and trifluoroacetic acid (4 mL) was added to react at room temperature for 2 hours. The crude product was concentrated under reduced pressure and ground with ethyl acetate (20 mL) to obtain a white solid powder 9 (860 mg, 90.7%).
[0320] 1 H NMR (Bruker AVANCE II, 400 MHz, DMSO- d 6): δ ppm 13.00 (s, 1H), 8.54– 8.53 (m, 1H), 8.32 – 8.31 (m, 1H), 8.27 (m, 1H), 4.91 (s, 2H), 2.78 (d, J=4.8 Hz, 3H).
[0321] LCMS: Rt = 0.444 min, MS (ESI) m / z = 212.2 [M+H] + .
[0322] Step 4: S )- N -methyl-3-(2-oxo-2-(7-(2-(trifluoromethyl)phenoxy)-5-azaspiro[2.4]hexan-5-yl)ethoxy)pyrazine-2-carboxamide
[0323] Compound 9 (300 mg, 1.42 mmol), compound 4 (580 mg, 1.56 mmol) and DIEA (1.8 g, 14.2 mmol) were dissolved in DMF solution (20 mL), TBTU (593 mg, 1.85 mmol) was added, and the mixture was reacted at room temperature for 2 hours. The mixture was diluted with ethyl acetate (100 mL), washed with water (2 × 50 mL) and saturated brine (50 mL). The organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and HPLC preparation (Gemini-C18 column, 5 μ silica gel, diameter 21.2 mm, length 150 mm) was used. The mobile phase was water (containing 0.05% TFA) and acetonitrile 35-55% to obtain white solid powder PCD-102-221008-006 (55.8 mg, 8.7%).
[0324] 1 H NMR (Bruker AVANCE II, 400 MHz, DMSO- d 6, 80℃): δ ppm 8.56 (d, J =4.0 Hz, 1H), 8.25 (s, 1H), 8.22 (dd, J = 2.4, 14.0 Hz, 1H), 7.65 – 7.58 (m,2H), 7.26 (dd, J = 8.4, 14.4 Hz, 2H), 7.11 (dd, J = 8.0, 16.0 Hz, 1H), 5.12 –5.02 (m, 2H), 4.81 (d, J = 4.0 Hz, 0.5H), 4.68 (d, J = 4.0 Hz, 0.5H), 4.09 (dd, J =4.0, 11.6 Hz, 0.5H), 3.87 (d,J = 9.6 Hz, 0.5H), 3.78 – 3.73 (m, 1H), 3.62 –3.59 (m, 1H), 3.41 (d, J = 9.6 Hz, 0.5H), 3.27 (d, J = 11.6 Hz, 0.5H), 2.77 (d, J =4.8 Hz, 3H), 0.95 – 0.66 (m, 4H).
[0325] HPLC: Rt = 5.581 min, purity: 99.93% (214 nm) and 100% (254 nm).
[0326] LCMS: Rt = 1.192 min, MS (ESI) m / z = 451.1 [M+H] + .
[0327] Example 3
[0328]
[0329] Example 3: S )-2-((3-chloropyrazin-2-yl)oxy)-1-(7-(2-(trifluoromethyl)phenoxy)-5-azaspiro[2.4]heptane-5-yl)ethanone
[0330] Step 1: tert-Butyl 2-((3-chloropyrazin-2-yl)oxy)acetate
[0331] NaH (349 mg, 8.73 mmol) was dissolved in dry DMF solution, and tert-butyl 2-glycolate (1.06 g, 8.05 mmol) was added under nitrogen protection at 0°C for 1 hour. Compound 10 (1 g, 6.71 mmol) was dissolved in DMF solution (10 mL), added to the reaction system at 0°C for 15 hours, quenched with saturated NH4Cl aqueous solution (10 mL), extracted with dichloromethane solution (100 mL), washed with water (2 × 30 mL) and saturated brine (30 mL). The organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and flash column chromatography (petroleum ether: ethyl acetate = 5:1) was performed to obtain yellow solid powder 11 (1.4 g, 84.8%).
[0332] 1H NMR (Bruker AVANCE II, 400 MHz, CDCl3): δ ppm 7.97 (s, 2H), 4.86 (s, 2H), 1.44 (s, 9H).
[0333] LCMS: Rt = 1.333 min, MS (ESI) m / z = 245.0 [M+H] + .
[0334] Step 2: 2-((3-chloropyrazin-2-yl)oxy)acetic acid
[0335] Compound 11 (1.4 g, 5.72 mmol) was dissolved in DCM solution (30 mL) and trifluoroacetic acid (6 mL) was added to react at room temperature for 2 hours. The mixture was concentrated under reduced pressure to obtain an off-white solid powder (940 mg, compound 12, 85.3%).
[0336] 1 H NMR (Bruker AVANCE II, 400 MHz, DMSO- d 6 ): δ ppm 13.14 (s, 1H), 8.23(d, J = 2.8 Hz, 1H), 8.13 (d, J = 2.8 Hz, 1H), 4.99 (s, 2H).
[0337] LCMS: Rt = 0.974 min, MS (ESI) m / z = 189.0 [M+H] + .
[0338] Step 3: S )-2-((3-chloropyrazin-2-yl)oxy)-1-(7-(2-(trifluoromethyl)phenoxy)-5-azaspiro[2.4]heptane-5-yl)ethanone
[0339] Compound 4 (300 mg, 1.59 mmol), compound 12 (649 mg, 1.74 mmol) and DIEA (1.03 g, 7.95 mmol) were dissolved in DMF solution (10 mL), TBTU (650 mg, 1.75 mmol) was added, and the mixture was reacted at room temperature for 2 hours. The mixture was extracted with ethyl acetate (100 mL), washed with water (2 × 50 mL) and saturated brine (50 mL). The organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and flash column chromatography (petroleum ether: ethyl acetate = 1:9) was performed to obtain a crude product. The product was then eluted with high performance liquid chromatography (Gemini-C18 column, 5 μ silica gel, 21 mm in diameter, 150 mm in length) using mobile phases: water (containing 0.05% TFA) and 30-40% acetonitrile to obtain yellow solid powder PCD-102-221008-007 (57 mg, 8.4%).
[0340] 1 H NMR (Bruker AVANCE II, 400 MHz, DMSO- d 6): δ ppm 8.13 (dd, J = 2.8,11.2 Hz, 1H), 8.10 – 8.08 (m, 1H), 7.64 – 7.58 (m, 1H), 7.28 – 7.21 (m, 1H),7.11 (dd, J = 7.6, 15.6 Hz, 1H), 5.17 – 5.07 (m, 2H), 4.81 (d, J = 4.0 Hz,0.5H), 4.68 (d, J = 3.6 Hz, 0.5H), 4.08 (dd, J = 4.4, 12.0 Hz, 0.5H), 3.88 (d, J = 9.6 Hz, 0.5H), 3.77 – 3.72 (m, 1H), 3.60 (dd, J = 3.2, 8.0 Hz, 1H), 3.39 (d, J = 9.6 Hz, 0.5H), 3.27 (d, J = 11.6 Hz), 0.94 – 0.69 (m, 4H).
[0341] HPLC: Rt = 6.520 min, purity: 100% (214 nm and 254 nm).
[0342] LCMS: Rt = 1.317 min, MS (ESI) m / z = 428.1 [M+H] + .
[0343] Example 4
[0344]
[0345] Example 4: S )-2-(4-hydroxymethylphenoxy)-1-(4-(2-trifluoromethylphenoxy)-6-azaspiro[2.5]octan-6-yl)ethan-1-one
[0346] Step 1: S )-tert-butyl 4-(2-trifluoromethylphenoxy)-6-azaspiro[2.5]octane-6-carboxylate
[0347] Compound 13 (13, 450 mg, 1.97 mmol), o-trifluoromethylphenol (353 mg, 2.17 mmol) and PPh3 (568 mg, 2.17 mmol) were dissolved in THF solution (30 mL), and DIAD (438 mg, 2.17 mmol) in THF solution (3 mL) was added dropwise under nitrogen protection at 0 °C. The reaction was quenched by adding 30 mL of aqueous solution, extracted with dichloromethane (3×30 mL), dried over anhydrous Na2SO4, concentrated under reduced pressure, and column chromatography (petroleum ether: ethyl acetate = 1:1) was performed to obtain a yellow oil 14 (170 mg, 20.8%).
[0348] 1 H NMR (Bruker, 400 MHz, DMSO- d 6) δ ppm 7.61 - 7.56 (m, 2H), 7.19 (d, J = 8.4 Hz, 1H), 7.06 (d, J = 7.6 Hz, 1H), 5.27 (m, 1H), 4.28 (d, J = 14.0 Hz,1H). 4.39 (s, 2H). 4.02 (t, J = 12.4 Hz, 1H). 3.88 (brs, 1H), 3.09 (d, J = 14.4Hz, 1H), 2.83 (t, J = 12.4 Hz, 1H), 2.16 (dd, J= 10.0, 14.4 Hz, 1H), 1.00 (s,9H), 0.81 (d, J = 13.6 Hz, 1H), 0.55 (brs, 2H), 0.44 (brs, 2H).
[0349] LCMS: Rt = 1.498 min, MS (ESI) m / z = 394.2 [M+Na] + .
[0350] Step 2: S )-4-(2-trifluoromethylphenoxy)-6-azaspiro[2.5]octane
[0351] Compound 14 (170 mg, 0.45 mmol) was dissolved in dichloromethane solution (6 mL), and trifluoroformic acid (1 mL) was added dropwise under nitrogen protection. The mixture was reacted at room temperature for 2 hours. The reaction mixture was concentrated and directly used for the next step.
[0352] LCMS: Rt = 1.045 min, MS (ESI) m / z = 272.0 [M+H] + .
[0353] Step 3: S )-2-(4-hydroxymethylphenoxy)-1-(4-(2-trifluoromethylphenoxy)-6-azaspiro[2.5]octan-6-yl)ethan-1-one
[0354] Compound 15 (120 mg, 0.44 mmol), 4-hydroxymethylphenoxyacetic acid (96 mg, 0.53 mmol) and DIEA (114 mg, 0.88 mmol) were dissolved in DMF solution (10 mL), and HATU (251 mg, 0.66 mmol) was added under nitrogen protection at room temperature for 16 hours. The reaction was quenched by adding 20 mL of water, extracted with dichloromethane (3×30 mL), and the organic layer was washed with saturated brine (2×30 mL), dried over anhydrous Na2SO4, concentrated under reduced pressure, and HPLC preparation (Gemini-C18 column, 5 µ silica gel, diameter 21.2 mm, length 150 mm, mobile phase: water (containing 0.05% TFA) and acetonitrile 10-60% gradient elution) was performed to obtain white solid powder PCD-102-220214-037 (60 mg, 30.6%).
[0355] 1 H NMR (Bruker AVANCE II, 400 MHz, DMSO- d6): δ ppm 7.63 - 7.53 (m, 2H),7.33 (dd, J = 8.0 Hz, 0.5H), 7.24 (d, J = 8.8 Hz, 0.5 Hz), 7.18-7.02 (m, 3H), 6.82 (d, J = 8.8 Hz, 1H), 6.62 (d, J = 8.4 Hz, 1H), 5.03 (ddd, J = 2.4, 6.0, 8.0Hz, 1H, OH), 4.76 (d, J = 14.8 Hz, 1H), 4.58 (d, J = 14.4 Hz, 0.5H), 4.38 (t, J =6.0 Hz, 2H), 4.26 (dd, J = 4.0, 13.6 Hz, 0.5H), 4.16 (m, 2H), 3.97 (dd, J = 3.2,14.4 Hz, 0.5H), 3.75 (m, 1H), 3.51 (d, J = 14.8 Hz, 0.5H), 3.31 - 3.23 (m,0.5H), 2.99 - 2.92 (m, 0.5H), 2.14 - 2.02 (m, 1H), 1.13 (m, 0.5H), 0.95 (m,0.5H), 0.60 (m, 2H), 0.50 - 0.41 (m, 2H).
[0356] HPLC: Rt = 6.068 min, purity: 99.50% (214 nm), 100% (254 nm).
[0357] LCMS:Rt = 1.285 min, MS (ESI) m / z = 436.0 [M+H] + .
[0358] Example 5 was prepared from compound implementation scheme 2.
[0359] Example 5
[0360]
[0361] Example 5: S)-2-4-Hydroxymethylphenoxy-1-(6-(2-trifluoromethylphenoxy))-4-azaspiro[2.4]heptane-4-yl)ethane
[0362] Step 1: R )-4-(tert-Butyldimethylsilyloxy)-2-pyrrolidone
[0363] Will( R )-4-Hydroxy-2-pyrrolidone (5 g, 49.5 mmol) and imidazole (6.74 g, 99 mmol) were dissolved in DMF solution (100 mL). TBSCl solution (9.7 g, 64.3 mmol) was slowly added dropwise under nitrogen protection at room temperature and reacted for 16 hours at room temperature. 100 mL of aqueous solution was added to the reaction system for dilution, and the mixture was extracted with ethyl acetate (3×100 mL). The organic layer was washed with aqueous solution (3×50 mL) and 50 mL of saturated brine in turn, dried over anhydrous NaS2O4, and concentrated under reduced pressure to obtain 17 as a white solid powder (7.9 g, 66.7%).
[0364] 1 H NMR (Bruker AVANCE II, 400 MHz, CDCl3) δ ppm 5.80 (brs, 1H, NH), 4.51 - 4.46 (m, 1H), 3.52 (dd, J = 6.0, 10.0 Hz, 1H), 3.17 (dd, J = 3.6, 10.0Hz, 1H), 2.47 (dd, J = 6.8 Hz, 17.2 Hz, 1H), 2.20 (dd, J = 4.0, 16.8 Hz, 1H), 0.81 (s, 9H), 0.01 (s, 6H).
[0365] LCMS: Rt = 1.250 min, MS Calcd.: 215.1, MS Found: 216.2 [M+H] + .
[0366] Step 2: R )-1-Benzyl-4-(tert-butyldimethylsilyloxy)-2-pyrrolidone
[0367] Will( R)-4-(tert-butyldimethylsilyloxy)-2-pyrrolidone (2 g, 9.3 mmol) was dissolved in anhydrous THF solution (40 mL). Under nitrogen protection at -10°C, 2.4 M n-BuLi hexane solution (4.6 mL, 11.1 mmol) was added dropwise. The reaction was continued at -10°C for 0.5 h. A THF solution of benzyl bromide (2.07 g, 12 mmol) was added and the reaction was continued at -10°C for 3 h. The reaction solution was quenched with saturated aqueous ammonium chloride solution (30 mL), extracted with ethyl acetate (3×50 mL), concentrated under reduced pressure, and purified by column chromatography (petroleum ether: ethyl acetate = 4:1) to obtain yellow solid powder 18 (1.5 g, 47.3%).
[0368] 1 H NMR (Bruker AVANCE II, 400 MHz, CDCl3) δ ppm 7.37 - 7.32 (m, 3H),7.24 - 7.22 (m, 2H), 4.59 (d, J = 14.8 Hz, 1H), 4.42 (d, J = 14.8 Hz, 1H), 4.39 -4.34 (m, 1H), 3.44 (dd, J = 5.6, 10.4 Hz, 1H), 3.12 (dd, J = 2.8, 10.4 Hz, 1H),2.66 (dd, J = 6.4, 16.8 Hz, 1H), 2.40 (dd, J = 3.2, 16.8 Hz, 1H), 0.85 (s, 9H), 0.04 (s, 3H), 0.01 (s, 3H).
[0369] LCMS: Rt = 1.448 min, MS Calcd.: 305.2, MS Found: 306.1 [M+H] + .
[0370] Step 3: R )-4-Benzyl-6-(tert-butyldimethylsilyloxy)-4-azaspiro[2.4]heptane
[0371] Ethylmagnesium bromide (17.1 mL, 17.1 mmol) was dissolved in anhydrous THF solution (40 mL). Tetraisopropyl titanate (8.36 g, 29.4 mmol) was added dropwise under nitrogen protection at -70°C. After stirring for 10 minutes, an anhydrous THF solution of compound 18 (1.5 g, 4.9 mmol) was added dropwise. The mixture was reacted at room temperature for 16 hours. The reaction was quenched with 50 mL of water and extracted with 3×50 mL of ethyl acetate. The mixture was dried over anhydrous Na2SO4, concentrated under reduced pressure, and subjected to column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain a yellow oil 19 (0.7 g, 40.8%).
[0372] 1 H NMR (Bruker AVANCE II, 400 MHz, CDCl3) δppm 7.29–7.18 (m, 5H), 4.47- 4.34 (m, 1H), 3.44 (d, J = 13.2 Hz, 2H), 2.90 (dd, J = 6.4, 10.8 Hz, 1H), 2.61(dd, J = 4.0, 10.8 Hz, 1H), 2.11 (dd, J = 7.6, 12.8Hz, 1H), 1.88 (dd, J = 4.4, 13.2Hz, 1H), 0.91–0.86 (m, 1H), 0.85 (s, 9H), 0.73 - 0.68 (m, 1H), 0.49 - 0.45(m, 1H), 0.37- 0.32 (m, 1H), 0.01 (s,3H), -0.01 (s,3H).
[0373] LCMS: Rt = 1.260 min, MS Calcd.: 317.2, MS Found: 318.1 [M+H] + .
[0374] Step 4: R )-4-Benzyl-4-azaspiro[2.4]heptan-6-ol
[0375] Will( R)-4-Benzyl-6-(tert-butyldimethylsilyloxy)-4-azaspiro[2.4]heptane (700 mg, 2.2 mmol) was dissolved in THF solution (6 mL), and TBAF solution (3.3 mL, 3.3 mmol) was added at room temperature, and the reaction was allowed to proceed for 4 hours at room temperature. The reaction was quenched with 30 mL of aqueous solution, extracted with ethyl acetate (3 × 50 mL), dried over anhydrous Na2SO4, concentrated under reduced pressure, and column chromatography (petroleum ether: ethyl acetate = 1:4) was performed to obtain colorless oil 20 (320 mg, 64.3%).
[0376] 1 H NMR (Bruker AVANCE II, 400 MHz, CDCl3) δ ppm 7.30 (m, 4H), 7.26 -7.21 (m, 1H), 4.41 - 4.37 (m, 1H), 3.45 (d, J = 12.8 Hz, 1H), 3.22 (d, J = 13.2Hz, 1H), 2.80 - 2.72 (m, 2H), 2.25 (dd, J = 7.2, 13.6 Hz, 1H), 1.94 - 1.91 (m,2H), 0.96 - 0.91 (m, 1H), 0.84 (m, 1H), 0.56 - 0.53 (m, 1H), 0.34 - 0.30 (m,1H).
[0377] LCMS: Rt = 0.524 min, MS Calcd.: 203.1, MS Found: 204.1 [M+H] + .
[0378] Step 5: S )-4-Benzyl-6-(2-trifluoromethyl-phenoxy)-4-azaspiro[2.4]heptane
[0379] Will( R)-4-Benzyl-4-azaspiro[2.4]heptan-6-ol (320 mg, 1.57 mmol), 2-hydroxytrifluorotoluene (282 mg, 1.73 mmol) and PPh3 (454 mg, 1.73 mmol) were dissolved in THF solution (20 mL). DIAD (350 mg, 1.73 mmol) was added at 0 °C and reacted at room temperature for 2 hours. The reaction was quenched with 30 mL of water, extracted with ethyl acetate (3×30 mL), dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by column chromatography (petroleum ether: ethyl acetate = 10:1) to obtain 21 (180 mg, 29.5%) as a yellow oil.
[0380] 1 H NMR (Bruker AVANCE II, 400 MHz, CDCl3) δ ppm 7.57 (d, J = 7.6 Hz,1H), 7.42 (t, J = 8.0 Hz, 1H), 7.34-7.20 (m, 5H), 6.97 (t, J = 7.6 Hz, 1H), 6.86(d, J = 8.4 Hz, 1H), 5.05 - 5.00 (m, 1H), 3.65 - 3.57 (m, 2H), 3.21 (dd, J = 6.4,12.4 Hz, 1H), 3.00 (dd, J = 2.8, 12.4 Hz, 1H), 2.35 (dd, J = 7.6, 13.6 Hz, 1H),2.18 (dd, J = 3.2, 13.6 Hz, 1H), 0.99 - 0.94 (m, 1H), 0.83 (brs, 1H), 0.63 -0.57 (m, 1H), 0.50 - 0.44 (m, 1H).
[0381] LCMS: Rt = 1.098 min, MS Calcd.: 347.1, MS Found: 348.2 [M+H] + .
[0382] Step 6: S )-6-(2-trifluoromethyl-phenoxy)-4-azaspiro[2.4]heptane
[0383] Will( S)-4-benzyl-6-(2-trifluoromethyl-phenoxy)-4-azaspiro[2.4]heptane (180 mg, 0.51 mmol) was dissolved in dichloroethane solution (10 mL), 1-chloroethyl chloroformate (221 mg, 1.55 mmol) was added, and the mixture was heated to 60 °C under nitrogen protection for 16 hours. The reaction was quenched with 10 mL of methanol solution, concentrated under reduced pressure, and column chromatography (petroleum ether: ethyl acetate = 1:5) was performed to obtain 22 as a white solid (100 mg, 67.5%).
[0384] 1 H NMR (Bruker AVANCE II, 400 MHz, CDCl3) δ ppm, 7.59 - 7.52 (m, 1H),7.46 (t, J = 8.8 Hz, 1H), 7.00 (t, J = 7.6 Hz, 1H), 6.94 (d, J = 8.0 Hz, 1H), 5.07(m, 1H), 3.30 (d, J = 12.8 Hz, 1H), 3.19 (dd, J = 4.8, 12.8 Hz, 1H), 2.19 (dd, J =6.4, 14.0 Hz, 1H), 2.02 (d, J = 14.0 Hz, 1H), 0.91 - 0.86 (m, 1H), 0.80 - 0.75 (m, 1H), 0.70 - 0.65 (m, 1H), 0.48 - 0.43 (m, 1H).
[0385] LCMS: Rt = 1.013 min, MS Calcd.: 257.1, MS Found: 258.1 [M+H] + .
[0386] Step 7: S )-2-4-Hydroxymethylphenoxy-1-(6-(2-trifluoromethylphenoxy))-4-azaspiro[2.4]heptane-4-yl)ethane
[0387] Compound 22 (100 mg, 0.39 mmol), 4-hydroxymethylphenoxyacetic acid (92 mg, 0.50 mmol) and DIEA (100 mg, 0.77 mmol) were dissolved in DMF solution (10 mL), and HATU (220 mg, 0.58 mmol) was added at room temperature under nitrogen protection, and the reaction was allowed to proceed at room temperature for 16 hours. The reaction was quenched by adding 20 mL of aqueous solution, extracted with dichloromethane (3×30 mL), dried over anhydrous Na2SO4, concentrated under reduced pressure, and subjected to preparative HPLC (Gemini-C18 column, 5 µ silica gel, 21.2 mm in diameter, 150 mm in length), with a mobile phase of water (containing 0.1% TFA) and acetonitrile 45-60% gradient elution, to obtain PCD-102-220214-041 (52 mg, 31.2%) as a colorless oil.
[0388] 1 H NMR (Bruker AVANCE II, 400 MHz, DMSO- d 6) δ ppm 7.65 - 7.61 (m, 2H),7.29 (d, J = 8.4 Hz, 1H), 7.18 (d, J = 8.4 Hz, 2H), 7.12 (t, J = 7.6 Hz, 1H), 6.78(d, J = 8.8 Hz, 2H), 5.27 (m, 1H), 5.03 (brs, 1H), 4.58 (s, 2H). 4.39 (s, 2H).4.04 (dd, J = 4.8, 12.0 Hz, 1H), 3.80 (d, J = 11.6 Hz, 1H), 2.48 (d, J = 4.8 Hz,1H), 1.99 (d, J = 2.4 Hz, 1H), 1.91 (d, J = 13.6 Hz, 1H), 1.57 (d, J = 11.6 Hz,1H), 0.49 (m, 2H).
[0389] HPLC: Rt = 6.081 min, Purity: 99.84% (214 nm) and 98.57% (254 nm).
[0390] LCMS: Rt = 1.264 min, MS Calcd.: 421.4 MS Found: 422.2 [M+H] + .
[0391] Pharmacological experiments
[0392] Detection of human subcutaneous preadipocytes
[0393] The role of SCD1 in adipocytes and epithelial cells is believed to be similar. Therefore, the ability of compounds to inhibit SCD1 in intact human cells was determined by using the AdipoRed assay. Human subcutaneous preadipocytes were differentiated for 5 days in 96-well plates, and the compounds of the invention were added at various concentrations over 14 days. Triglyceride production was then measured using the AdipoRed dye, which binds to secreted triglycerides. The ability to inhibit triglyceride production was measured as IC 50 Value to represent.
[0394] Experimental Methods for Detecting Human Subcutaneous Preadipocytes
[0395] Cryopreserved human subcutaneous preadipocytes (Cat. No.: PT-5020, Lonza) were thawed at 37°C, and the subcutaneous preadipocytes were transferred to 9 mL of pre-warmed pre-adipocyte growth medium (Cat. No.: PT8002, Lonza) and centrifuged at 1000 rpm for 10 minutes. After discarding the supernatant, 1 mL of pre-warmed pre-adipocyte growth medium-2 was added to the wells, and 100 μL of cell suspension was added to each well of the 96-well plate (Corning 3904). The cell count showed that there were approximately 3000 cells / 100 μL per well, and the plates were incubated in an incubator at 37°C, 5% CO2 for 2 days. 100 μL of cell growth medium was added to the undifferentiated pre-adipocyte control wells (blank control 1, 4 wells). 100 μL of 2× differentiation medium was added to the remaining plates, and the plates were incubated in an incubator at 37°C, 5% CO2 for 5 days to induce cell differentiation.
[0396] After 5 days of differentiation, the medium in the wells was discarded, and 200 μL of cell growth medium was added to the undifferentiated preadipocytes (blank control 1, 4 wells). 100 μL of 2× differentiation medium and 100 μL of cell growth medium were added to the differentiated preadipocytes (blank control 2, 4 wells). The highest concentration of PCD-102-211130-001 (positive control compound) and the test sample was 1 μM, and DMSO was used to dilute from the highest concentration 3 times to the lowest concentration, with a total of 10 concentration gradients, and each concentration was tested 4 times in parallel. 100 μL of 2× differentiation medium and 100 μL of cell growth medium containing different concentrations of compounds were added to the plate wells for positive control and test sample detection, respectively, and incubated in an incubator at 37°C, 5% CO2 for 14 days.
[0397] After 14 days of treatment with the compound, the 96-well plate containing the differentiated adipocytes was washed twice with PBS, and 200 μL of PBS was added to each well. The plates were stained with 5 μL of AdipoRed (Cat. #: PT-7009, Lonza) reagent for 15 minutes at room temperature. The plates were then read in fluorescence polarization mode on a BMG LABTECH (CLARIO starPlus) multi-function microplate reader, Ex = 485 nM / Em = 572 nM, to quantify the accumulation of intracellular triglycerides.
[0398] Using the above detection method, the IC of the compound of the present invention was measured. 50 See Table 1 for values.
[0399] Table 1. Test results of human subcutaneous preadipocytes of the present invention
[0400] Compound Name <![CDATA[IC 50 ]]> Example 1 247.2 nM Example 2 1 μM-10 μM Example 3 1 μM-10 μM Example 4 1 μM-10 μM Example 5 1 μM-10 μM
[0401] All patents, patent applications, and publications cited in this application are hereby incorporated by reference in their entirety to the same extent as if each individual patent, patent application or publication were individually incorporated by reference.
[0402] Although the present invention has been described by reference to the embodiments of the present invention, such reference is not meant to limit the present invention, and various modifications may be made without departing from the spirit and scope of the present invention. Therefore, the present invention is limited only by the appended claims.
Claims
1. A compound represented by formula (I): (I) or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer or racemate thereof; in, m and n are each independently 0 or 1; X and Y together form a cyclopropyl, cyclobutyl or cyclopentyl group; U and V together form a cyclopropyl, cyclobutyl or cyclopentyl group; W is an oxygen atom; Q is independently selected from aryl or heteroaryl; R1 is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C3-C6 cycloalkyl, halogen, optionally halogenated C1-C6 alkyl, C1-C6 alkoxy, optionally halogenated C1-C6 alkoxy, C3-C6 cycloalkyloxy, optionally halogenated C3-C6 cycloalkyloxy; R2 is independently selected from hydrogen, hydroxy, hydroxy-substituted C1-C6 alkyl, C1-C6 alkyl, C3-C6 cycloalkyl, halogen, optionally halogenated C1-C6 alkyl, C1-C6 alkoxy, optionally halogenated C1-C6 alkoxy, C3-C6 cycloalkyloxy, optionally halogenated C3-C6 cycloalkyloxy, alkoxyalkyl, nitro, cyano, aminosulfonyl, amino, C1-C6 alkylamino, -C(O)NH(R3); R3 is independently selected from hydrogen or C1-C6 alkyl.
2. The compound according to claim 1, the compound of formula (Ia) (Ia) or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer, or racemate thereof; in, m is independently 0 or 1; U and V together form a cyclopropyl, cyclobutyl or cyclopentyl group; W is an oxygen atom; Q is independently selected from aryl or heteroaryl; R1 is independently selected from hydrogen, halogen, optionally halogenated C1-C6 alkyl; R2 is independently selected from hydrogen, hydroxy, hydroxy-substituted C1-C6 alkyl, C1-C6 alkyl, C3-C6 cycloalkyl, halogen, optionally halogenated C1-C6 alkyl, C1-C6 alkoxy, optionally halogenated C1-C6 alkoxy, C3-C6 cycloalkyloxy, optionally halogenated C3-C6 cycloalkyloxy, alkoxyalkyl, nitro, cyano, aminosulfonyl, amino, C1-C6 alkylamino, -C(O)NH(R3); R3 is independently selected from hydrogen or C1-C6 alkyl.
3. The compound according to any one or both of claims 1 and 2, the compound of formula (Ib) (Ib) or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer or racemate thereof; in, U and V together form a cyclopropyl, cyclobutyl or cyclopentyl group; Q is independently selected from aryl or heteroaryl; R1 is independently selected from hydrogen, halogen, optionally halogenated C1-C6 alkyl; R2 is independently selected from hydrogen, hydroxy, hydroxy-substituted C1-C6 alkyl, C1-C6 alkyl, C3-C6 cycloalkyl, halogen, optionally halogenated C1-C6 alkyl, C1-C6 alkoxy, optionally halogenated C1-C6 alkoxy, C3-C6 cycloalkyloxy, optionally halogenated C3-C6 cycloalkyloxy, alkoxyalkyl, nitro, cyano, aminosulfonyl, amino, C1-C6 alkylamino, -C(O)NH(R3); R3 is independently selected from hydrogen or C1-C6 alkyl.
4. The compound according to any one or more of claims 1 to 3, the compound of formula (Ic) (Ic) or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer or racemate thereof; in, Q is independently selected from aryl or heteroaryl; R1 is independently selected from trifluoromethyl or halogen; R2 is independently selected from hydrogen, hydroxy, hydroxy-substituted C1-C6 alkyl, halogen, -C(O)NH(R3); R3 is independently selected from hydrogen or C1-C6 alkyl.
5. A compound according to any one or more of claims 1 to 4, wherein R1 is trifluoromethyl and Q is independently selected from , ; R2 is independently selected from hydroxy-substituted C1-C6 alkyl, halogen, -C(O)NH(R3); R3 is independently selected from hydrogen or C1-C6 alkyl.
6. The compound according to any one or both of claims 1 and 2, the compound of formula (Id) (Id) or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer or racemate thereof; in, R1 is independently selected from trifluoromethyl or halogen; R2 is independently selected from C1-C6 alkyl substituted with hydroxy, C1-C6 alkyl.
7. The compound according to claim 1, the compound of formula (Ie) (Ie) or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, isotope-labeled compound, stereoisomer, tautomer or racemate thereof; in, R1 is independently selected from trifluoromethyl or halogen; R2 is independently selected from C1-C6 alkyl substituted with hydroxy.
8. The compound according to any one or more of claims 1 to 7, wherein the compound is selected from the following: 1) , 2) , 3) , 4) , 5) or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
9. A pharmaceutical composition comprising the compound according to any one of claims 1 to 8, and a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a vehicle, a diluent and an excipient.
10. Use of the compound of any one of claims 1 to 8 or the pharmaceutical composition of claim 9 in the preparation of a medicament for treating and / or preventing a stearoyl-CoA desaturase 1-mediated related disorder, disease or condition in a patient.
11. The use according to claim 10, wherein the stearoyl-CoA desaturase 1-mediated disorder, disease or condition is selected from lipid disorders, metabolic syndrome, weight disorders, skin diseases, fatty liver disease, diabetes and cancer.
12. The use according to claim 11, wherein the disorder, disease or condition is selected from a combination of dyslipidemia, hyperlipidemia, hypertriglyceridemia, atherosclerosis, hypercholesterolemia, low high-density lipoprotein and high low-density lipoprotein, dyslipidemia, diabetes, impaired glucose tolerance, obesity, insulin resistance, hypertension, hypertriglyceridemia, increased abdominal circumference, low high-density lipoprotein, microalbuminemia, hyperuricemia and / or hypercoagulability.
13. The use according to claim 11, wherein the disorder, disease or condition is selected from eczema, acne, rosacea, seborrheic dermatitis, oily skin, rosacea, keloid scarring or other skin conditions caused by lipid imbalance.
14. The use according to claim 11, wherein the disorder, disease or condition is selected from non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cirrhosis.
15. The use according to claim 11, wherein the disorder, disease or condition is selected from renal cell carcinoma, liver cancer, bladder cancer, breast cancer, lung cancer, prostate cancer, ovarian cancer, colon cancer, melanoma, pancreatic cancer, thyroid cancer.
16. The use according to claim 10, wherein the stearoyl-CoA desaturase 1-mediated disorder, disease or condition is selected from lipid disorders, metabolic syndrome, weight disorders, skin diseases, fatty liver disease, diabetes and cancer and the method further comprises administering a second therapeutic agent for treating and / or preventing lipid disorders, metabolic syndrome, weight disorders, skin diseases, fatty liver disease, diabetes and cancer.
